

## CURRICULUM VITAE

**Kim D. Janda, Ph.D.**

*Ely R. Callaway Jr. Professor in Chemistry  
Director, The Worm Institute of Research & Medicine (WIRM)*

**Address:** The Scripps Research Institute  
Department of Chemistry  
10550 North Torrey Pines Road  
Maildrop: BCC-582  
La Jolla, CA 92037  
Tel.: (858) 784-2516  
Fax: (858) 784-2595  
[kdjanda@scripps.edu](mailto:kdjanda@scripps.edu)  
[www.scripps.edu/janda](http://www.scripps.edu/janda)

### **Education:**

- 1980 B.S. Clinical Chemistry, University of South Florida  
1983 M.S. Organic Chemistry, University of Arizona  
Thesis title: Synthesis of Diphenyl Ethers as Related to the Anti-tumor Agent Deoxybouvardin.  
1984 Ph.D. Organic Chemistry Major, Medicinal Chemistry Minor, University of Arizona  
Dissertation title: Progress Towards a Synthesis of Deoxybouvardin and Analogues: New Synthetic Methods.

### **Professional Record:**

- 1985-1986 *Postdoctoral Fellow*, Department of Molecular Biology  
Research Institute of Scripps Clinic, La Jolla, CA  
1987-1988 *Adjunct Assistant Professor*, Department of Molecular Biology  
Research Institute of Scripps Clinic, La Jolla, CA  
1989-1990 *Assistant Professor*, Department of Molecular Biology  
Research Institute of Scripps Clinic, La Jolla, CA  
1991-1992 *Associate Professor*, Departments of Molecular Biology and Chemistry  
The Scripps Research Institute, La Jolla, CA  
1993-1996 *Associate Professor* (tenured), Departments of Molecular Biology and Chemistry  
The Scripps Research Institute, La Jolla, CA  
1996 *Associate Professor*, The Skaggs Institute for Chemical Biology  
(joint appointment), The Scripps Research Institute, La Jolla, CA  
1996-present *Professor*, Department of Chemistry  
The Scripps Research Institute, La Jolla, CA

- 1996-present *Ely R. Callaway Jr. Chair in Chemistry*  
The Scripps Research Institute, La Jolla, CA
- 1996-present *Skaggs Scholar*  
The Skaggs Institute for Chemical Biology, La Jolla, CA
- 2005-present *Professor*, Department of Immunology and Microbial Science  
(joint appointment), The Scripps Research Institute, La Jolla, CA
- 2005-present *Director*, The Worm Institute of Research & Medicine (WIRM)  
The Scripps Research Institute, La Jolla, CA

**Honorary, Professional Organizations and Awards:**

- 1979-1980 Scholar Athlete of the Year, University of South Florida
- 1980 Magna Cum Laude; Phi Beta Kappa, University of South Florida
- 1981-present Member, American Chemical Society
- 1984 Carl S. Marvel Fellowship, University of Arizona
- 1986 Fellow, American Institute of Chemists
- 1990-1995 NIH FIRST Award
- 1993-1995 Alfred P. Sloan Fellowship
- 1995 Zeneca Lectuer, Colorado State University
- 1999 Arthur C. Cope Scholar Award
- 2000 J. Clarence Karcher Lecturer, University of Oklahoma
- 2001 Outstanding Alumnus in Chemistry, University of South Florida
- 2002 Shire BioChem Lecturer, Universite de Montreal, Montreal, Canada
- 2002 Rayson Huang Visiting Lecturer, University of Hong Kong, Hong Kong, China
- 2002 Sigma-Aldrich Lecturer, Milwaukee Section ACS, Milwaukee, WI
- 2003 Keynote Speaker, Graduate Student Symposium, University of Michigan
- 2003 GSO Speaker, University of North Carolina
- 2003 Biomolecular Student Lecturer, Emory University
- 2003 Elected Fellow of American Association for the Advancement of Science
- 2006 Office of Life Sciences Distinguished Lecture, National University of Singapore
- 2006 Discover magazine's "Top 100 Science Stories of 2006" for Obesity Vaccine work
- 2009 Doctor of Philosophy honoris causa, University of Helsinki, Finland
- 2009 E. Lilly Distinguished Lecturer
- 2010 Harold A. Iddles Lecture, Chemistry Dept, University of New Hampshire, Durham
- 2010 Harvey W. McFadden, Jr., M.D. Lecture, Department of Pathology & Microbiology, University of Nebraska Medical Center
- 2010 Molecule of the Week (3,4-Diaminopyridine), American Chemical Society, (January 10, 2011)
- 2012 Arran Thomas Amadeo Streppa Memorial Lecture, Sealy Center for Vaccine Development Symposium
- 2012 10<sup>th</sup> Raymond N. Castle Student Research Conference Plenary Lecture, University of Southern Florida

- 2015 Path to Recovery Honoree, presented by A New PATH (Parents for Addiction Treatment & Healing), for developing research towards a heroin addiction vaccine
- 2015 Xingda Lecturer, Peking University, College of Chemistry, Beijing, China
- 2015 Distinguished Seminar Lectureship Speaker, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota
- 2017 ACS Alfred Bader Award in Bioorganic Chemistry
- 2019 Wolk Lectureship Speaker, Colgate University
- 2019 Portuguese Lectureship Award, ACS Division of Medicinal Chemistry
- 2019 Tai Lectureship in Innovative Therapeutics Award, University of Kentucky, College of Pharmacy

**Previous External Committees and Boards:**

- 2008-2010 Investment Committee, The Skaggs Institute for Research
- 2006-2010 Member of the Board of Trustees, The Skaggs Institute for Research

**Editorial Positions:**

- 1997-2003 *Combinatorial Chemistry and High-Throughput Screening*, Editorial Board
- 1997-2003 *Combinatorial Chemistry Research and Applications*, Editorial Board
- 1999-2004 *Journal of Combinatorial Chemistry*, Editorial Board
- 2002-2014 *Chemical Reviews*, Advisory Board
- 2004-present *Bioorganic & Medicinal Chemistry Letters*, Advisory Board
- 2008-2019 *Bioorganic & Medicinal Chemistry*, Associate Editor
- 2008-2019 *Bioorganic & Medicinal Chemistry*, American Regional Editor
- 2008-present *Journal of Medicinal Chemistry*, Advisory Board
- 2008-present *Tetrahedron Publications*, Executive Board of Editors
- 2009-2010 *The Botulinum Journal*, Advisory Board
- 2009-present *Immunotherapy*, Editorial Board
- 2010-present *Beilstein Journal of Organic Chemistry*, Advisory Board
- 2011-2014 *PLoS ONE*, Associate Editor

**Companies Founded:**

- CombiChem, founded in 1994, acquired by Dupont in 1999
- Drug Abuse Sciences, founded in 1994
- AlPartia Pharmaceuticals, founded in 2008
- Cessation Therapeutics, founded in 2018

**Current Consulting Agreements:**

- Sorrento Therapeutics, Inc.

**Scientific Advisory Boards:**

- Sorrento Therapeutics, Inc.

- MindX Sciences
- Aadvark
- Amyloid Solutions

**Scientific Advisory Positions held previously:**

- Drug Abuse Sciences
- Joint Scientific Council Committee, Novartis/TSRI
- Steering Committee, Novartis/TSRI
- EPIcyte Pharmaceutical, Inc.
- Chembiotek Research International (TAB)
- ProKinase Research Consortium
- EU Integrated Project: “Protein kinases – Novel drug targets of post genomic era”

**Peer Review Committees:**

1993	Department of Energy (Materials Science Section)
1994	National Science Foundation (Bioorganic Section)
1994	National Institutes of Health (Bioorganic and Natural Products Section)
1996-1999	Long Range Planning Committee, ACS Medicinal Chemistry
1997-1999	NIDA Special Emphasis Study Section
2001	NIH Special Study Section B
2002	NIAID Study Section: Partnerships for Novel Therapeutics, Diagnostic and Vector Control Strategies in Infectious Diseases
2002	NSF CAREER Development Award Study Section
2003	NIAID Study Section (Chairman): Collaborative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics, and Diagnostics for Biodefense
2003	NIAID Study Section (Chairman): Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research
2004	NIAID Study Section: Enhancement Awards for Underrepresented Minority Scientists
2004	NIH Special Emphasis Panel on Bacterial Pathogenesis
2004	NIGMS Bioorganic and Natural Products Chemistry Study Section
2005	NIDA Training and Career Development Study Section
2006-2016	Singapore Ministry of Education (MOE), Chairman Physical Sciences
2007	Breast Cancer Research Program (BCRP)- Concept-Clinical and Experm. Therapeutics
2007	DOD Congressionally Directed Medical Research Program (CDMRP)
2007	NIH Study Section (Chairman): Cooperative Research into Therapeutics and Diagnostics for Category B Bacteria, Viruses, and Parasites
2007	NIH Study Section: Myocardial Ischemia and Metabolism
2008	NIDA Special Emphasis Panel Meeting for Members of the International Collaborations for HIV and Drug Abuse (R21) Review Committee, April 2
2008	International Cancer Stem Cell Workshop, Toronto, Canada, April 17-18

2009	NIH Challenge Grants Panel 9
2009	NIH Challenge Grant Panel 17
2009	NIH Pilot-Scale Libraries for High-Throughput Screening
2010	NIH Special Emphasis Panel on Countermeasures Against Chemical Threats
2011	NIH Special Emphasis Panel on Countermeasures Against Chemical Threats
2012-2017	VMD Study Section: Vaccines Against Microbial Diseases
2010-2014	Singapore Ministry of Education (MOE), Chairman, AcRF Tier 2 EP1 Meeting
2014	Chairman, 15 <sup>th</sup> Tetrahedron Symposium
2014	Chairman, 15 <sup>th</sup> Tetrahedron Asia Symposium
2016-2017	NIH Special Emphasis Panel on Non-HIV Anti-Infective Therapeutics
2017	NIH Special Emphasis Meeting on Medications Development for Opioid Use Disorders and Overdose Prevention and Reversal
2018	NIGMS Special Emphasis Panel to review "Maximizing Investigator's Research Award" (MIRA) applications for Early-Stage Investigators (ESIs).

### **Invited Lectures:**

1. Gordon Research Conf. on Proteolytic Enzymes and Their Inhibitors, New Hampshire, June 8, 1988.
2. European Molecular Biology Laboratory, Heidelberg, Germany, August 20, 1988.
3. 196th ACS National Meeting, Los Angeles, CA, September 5, 1988.
4. Lake Tahoe Symposium, Genetic Engineering/Immune System, Lake Tahoe, NV, October 3, 1988.
5. 1988 Pacific Conf. on Chemistry & Spectroscopy, San Francisco, CA, October 26, 1988.
6. 197th ACS National Meeting, Dallas, TX, April 9, 1989.
7. American Society for Microbiology Biotechnological Conference, Orlando, FL, June 22, 1989.
8. American Assc. of Pharmaceutical Scientists, Frontiers of Biotech., Atlanta, GA, October 22, 1989.
9. American Inst. of Chem. Eng., Prod. of Specialty Chemicals, San Francisco, CA, November 5, 1989.
10. University of Tokyo, Department of Agriculture, Tokyo, Japan, January 22, 1990.
11. Tokyo Institute of Technology, Tokyo, Japan, January 23, 1990.
12. Research Institute of Chemical Engineering, Tsukuba, Japan, January 24, 1990.
13. 9th Science and Technology Forum, Tsukuba, Japan, January 24, 1990.
14. Pan-Am. Assc/BioMed Soc, Protein Structure/Function, Novel Exp. Approaches, Brazil, Feb.18, 1990.
15. R.W. Johnson Pharmaceutical Research Institute, San Diego, CA, March 28, 1990.
16. George E. Hewitt Foundation for Medical Research, Irvine, CA, March 30, 1990.
17. Pharmaceutical Society of Japan, Kyushu University, Fukuoka, Japan, May 21, 1990.
18. Kanebo, Ltd., Pharmaceutical Research Center, Osaka, Japan, May 22, 1990.
19. The Green Cross Corporation, Osaka, Japan, May 23, 1990.
20. Unitika Research and Development Center, Kyoto, Japan, May 24, 1990.
21. Protein Engineering Research Institute, Osaka, Japan, May 25, 1990.

22. Bio Japan 90, Protein Engineering-Structure & Function, Osaka, Japan, May 23, 1990.
23. 1990 ASM Conference on Biotechnology, Chicago, IL, June 7, 1990.
24. Ciba Foundation Symposium, London, England, September 1-October 3, 1990.
25. American Institute of Chemical Engineers Meeting, Chicago, IL, November 11, 1990.
26. Annenberg Ctr./Frontiers in Biomedical Research 1991, Rancho Mirage, CA, February 17, 1991.
27. Osaka University, Department of Polymer Science, Osaka, Japan, March 24, 1991.
28. Kanebo, Ltd., Osaka, Japan, March 25, 1991.
29. Tanabe Seiyaku Co., Ltd., Osaka, Japan, March 26, 1991.
30. Sekisui Chemical Co., Osaka, Japan, March 27, 1991.
31. ABC Symposium, Kyoto, Japan, March 28, 1991.
32. Florida Conference on Catalysis, Daytona, FL, April 8, 1991.
33. Sterling Drug Co., Albany, NY, June 7, 1991.
34. New Zealand Inst. Chem./Biochemical Society/Jubilee Conf. Univ. Canterbury, August 26, 1991.
35. International Biotechnology Expo & Scientific Conference, San Francisco, CA, October 6, 1991.
36. University of Arizona, Department of Chemistry, October 28, 1991.
37. The Scripps Research Institute, Structure and Affinity Lecture Series, January 9, 1992.
38. Receptor Laboratories, Inc., Chicago, IL, January 20, 1993.
39. Shanghai Research Centre of Biotechnology, Shanghai, China, June 1, 1993.
40. Toyobo Pharmaceutical Co., Osaka, Japan, June 2, 1993.
41. Inter. Workshop on Chemistry/Biochemistry of Biocatalysis, Kyoto-Fu, Japan, June 3, 1993.
42. Inter. Un. of Pure & Applied Chem., 2nd Inter. Symp. on Bioorganic Chem, Japan, June 6, 1993.
43. Second International Symposium on Bioorganic Chemistry, Fukuoka, Japan, June 6, 1993.
44. Shanghai Institute of Cell Biology, Chinese Academy of Sciences, China, June 14, 1993.
45. Nat. Key Lab. Bioorg/Nat. Prod. Chem/Chinese Academy of Sciences, Shanghai, China, June 15, 1993.
46. Fudan University, Institute of Genetics, Shanghai, China, June 15, 1993.
47. Biochemical Society, Biological Chemistry, Sheffield, England, July 23, 1993.
48. NIH, NIAID, Rocky Mountain Laboratories, Hamilton, MT, August 11, 1993.
49. Monoclonal Antibodies from Combinatorial Libraries, Cold Spring Harbor, November 12, 1993.
50. Ab Eng/ Resch & Applic/Genes Encoding Immunoglobulins Symp., Lake Tahoe, CA, March 8, 1994.
51. University of British Columbia, Vancouver, Canada, Dept. of Chemistry, March 22, 1994.
52. Unilever Research Center, Edgewater, NJ, April 4, 1994.
53. Tokyo Institute of Technology, IMSC, PERI, Kanebo, Sankyo, Japan, April 7, 1994.
54. World Molecular Engineering Network-4th Conf., San Jose de Cabo, Mexico, April 24, 1994.

55. Enzymes/Coenzymes/Metabolic Pathways, Gordon Conference, New Hampshire, July 17, 1994.
56. Chemical Reaction Mechanisms Conference, plenary lecture, Helsinki, Finland, September 27, 1994.
57. University of Illinois, Department of Chemistry, October 26, 1994.
58. Oligonucleotide Selection and Molecular Diversity, Lake Tahoe, CA, October 29, 1994.
59. Time-Machine-Bio, Molecular Evolution Engineering, Tsukuba, Japan, November 7, 1994.
60. Monoclonal Antibodies from Combinatorial Libraries, Cold Spring Harbor, November 17, 1994.
61. Synthesis Symposium, plenary lecture, University of California Irvine, December 10, 1994.
62. Exploiting Molecular Diversity, Small Molecule Libraries for Drug Disc. San Diego, CA January 24, 1995.
63. Exploiting Biological Div. Libraries/Mutations for Research/Drug Dev., San Diego, CA, January 26, 1995.
64. Frontiers of Biomedical Research, Palm Springs, CA, February 19, 1995.
65. 10th Inter. Conf. Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA, March 10, 1995.
66. Brigham Young University, Department of Chemistry, Provo, UT, March 14, 1995.
67. Colorado State Univ., Dept. of Chemistry, Zeneca Distinguished Lecturer, April 20, 1995.
68. IBC's High Throughput Screening Conference, San Francisco, CA, May 17, 1995.
69. 5th Mtg French-Amer. Chem. Society (PACSV), Bordeaux, France, June 25, 1995.
70. Brandeis University, Department of Chemistry, Massachusetts, September 20, 1995.
71. MIT, Department of Chemistry, Massachusetts, September 21, 1995.
72. UCLA, Department of Chemistry, Los Angeles, CA, October 5, 1995.
73. Abbott Laboratories, Chicago, IL, October 11, 1995.
74. American Chemical Society, Western Regional Meeting, October 18, 1995.
75. Shanghai Research Centre of Biotechnology, China, November 5, 1995.
76. University of Southern California, Department of Chemistry, November 15, 1995.
77. Am. Chem. Soc. SE Reg. Mtg; Chem. Lib., Peptides/Peptidomimetics, Memphis, TN, Nov. 29, 1995.
78. Comb. Library Methods/Basic Research & Drug Disc., AZ Cancer Center, Tucson, AZ, December 2, 1995.
79. Inter. Chem. Cong/P. Basin Societies, Biocatalysis/Org. Synthesis, Honolulu, HA, December 17, 1995.
80. IBC USA Conf. on Mol. Diversity & Combinatorial Chemistry, San Diego, CA, January 24, 1996.
81. Cambridge Healthtech Inst., Solid Phase Synthesis Symposia, San Diego, CA, February 1, 1996.
82. TSRI/R.W. Johnson Pharm. Rsch. Inst. Collab. Resch. Projects Sci. Mtg, La Jolla, CA, Feb 13, 1996.
83. Frontiers in Biomedical Research, Indian Wells, CA, February 18, 1996.
84. Combinatorial Chemistry '96', San Diego, CA, March 21, 1996.

85. 211th ACS National Meeting, New Orleans, LA, March 24, 1996.
86. Drug Abuse Sciences, Inc., San Francisco, CA, April 3, 1996.
87. Bracco Research USA, Inc., Princeton, NJ, April 8, 1996.
88. ROHM & HAAS Co., Spring House, PA, April 10, 1996.
89. Merck Frost Centre for Therapeutic Research, Quebec, Canada, April 22, 1996.
90. World Mol. Engineering Network 6th Meeting/Structural Biology, del Cabo, April 28, 1996.
91. UCSD, Department of Chemistry & Biochemistry, La Jolla, CA, May 6, 1996.
92. NAPP Systems, Inc., San Marcos, CA, May 14, 1996.
93. Drug Abuse Sciences, Inc., San Francisco, CA, May 14, 1996.
94. 1996 National Medicinal Chemistry Symposium, Ann Arbor, MI, June 18, 1996.
95. Antibody-and Protein-based Therapies for Drug Abuse, Puerto Rico, June 22, 1996.
96. IBC USA Conference, Southborough, MA, August 19, 1996.
97. ETH, Eidgenossische Technische Hochschule, Zürich, Switzerland, September 9, 1996.
98. 18th Annual Princeton ACS Fall Org. Chem. Symp., Princeton, NJ, September 26, 1996.
99. 1st French Symposium on Combinatorial Chemistry, Rennes, France, October 29, 1996.
100. Inventor Showcase/Corp. Partnership, UCSD, San Diego, CA, Sheraton, November 12, 1996.
101. Loma Linda University, Loma Linda, CA, November 20, 1996.
102. Procter and Gamble, Cincinnati, OH, December 9, 1996.
103. Winter Conf./Med.& Bioorganic Chem., Steamboat Springs, CO, January 25, 1997.
104. Yale University, New Haven, CT, February 5, 1997.
105. CHI's (Cambridge Health Inst.) Solid Phase Synthesis, Coronado, CA, February 6, 1997.
106. American Assc. For Advancement of Science AMSIE, Seattle, WA, February 13, 1997.
107. Frontiers in Biomedical Research, Indian Wells, CA, Hyatt Grand Champions, February 16, 1997.
108. University of Chicago (Closs Lecture), February 28, 1997.
109. Ciba-Geigy Corp./Novartis, ACS, Summit, NJ, March 24, 1997.
110. University of Kentucky, 23rd Symposium on Chemistry & Molecular Biology, April 8, 1997.
111. University of Helsinki, Finland, April 11, 1997.
112. Lawrence Berkeley Nat. Lab., Structural Bio. Div. Rev. Com., Div. Director, April 20-21, 1997.
113. University of Toronto, Canada, April 25, 1997.
114. 31st European Symposium on Bioorganic Chemistry (ESBOC), Gregynog, Wales, May 9, 1997.
115. 15th APS Frontiers of Peptide Science, Nashville, TN, June 14, 1997.
116. Joint Scientific Council, Novartis, Basel, Switzerland, June 26, 1997.
117. Comb. Approaches/Chem/Biology, Churchill Coll., Cambridge Univ., England, July 27, 1997.
118. Org. Reactions & Processes/Gordon Research Conference, New Hampshire, August 3, 1997.
119. Long Range Planning Committee, ACS Division of Medicinal Chemistry, September 8, 1997.



120. Drug Abuse Sciences, Inc., SAB Meeting, September 20, 1997.
121. Northwestern University, Evanston, IL, October 3, 1997.
122. University of Texas at San Antonio, TX, October 16, 1997.
123. Wenner-Gren/Chem/Bio Libraries/Ligand Design, Stockholm, Sweden, November 5, 1997.
124. IBC Conference/Antibody Engineering, San Diego, CA, December 3, 1997.
125. University of Texas, Southwestern Medical Center, January 22, 1998.
126. Lake Tahoe Center, 2nd Inter. Symp. on Mol. Diversity, Lake Tahoe, CA, January 24, 1998.
127. Frontiers of Biomedical Research Symposium, Indian Wells, CA, February 1, 1998.
128. ACS 14th Rocky Mtn. Reg. Mtg, Comb. Chem./Robotics, Tucson, AZ, March 15, 1998.
129. Pharmacia & Upjohn, Inc., Kalamazoo, MI, April 13, 1998.
130. University of Virginia, April 24, 1998.
131. NIDA, Rockville, MD, April 27, 1998.
132. University of California, Berkeley, CA, April 28, 1998.
133. Gilead Sciences, Foster City, CA, April 29, 1998.
134. NIH Review, Washington D.C., June 1, 1998.
135. Università Degli Studi Di Milano, Venice, Italy, June 28, 1998.
136. 12th Intern. Conf. on Organic Synthesis ICOS-12, Venice, Italy, June 28, 1998.
137. 14th Triennial Inter. Conf. in Phosphorus Chem., ICPC, Cincinnati, OH, July 12, 1998.
138. Ligand Pharmaceuticals, San Diego, CA, July 23, 1998.
139. Gordon Conference, New Hampshire, August 16, 1998.
140. ACS National Meeting, Boston, MA, August 23, 1998.
141. The Dupont Company, Wilmington, DE, September 14, 1998.
142. Hoechst Marion Roussel, Inc, September 29, 1998.
143. 3rd Aust. Pept. Conf "From Disc. to Therapeutics", Whitsunday Islands, October 4, 1998.
144. ASTA Medica, Schliersee Symp "Speeding Up Drug Discovery", Germany, October 14, 1998.
145. Exploiting Molecular Diversity, San Diego, CA, February 1, 1999.
146. Frontiers in Biomedical Research, February 7, 1999.
147. NIDA Med. Dev. Special Emphasis Panel (SEP), Washington, D.C., February 23, 1999.
148. University of Alberta, Edmonton, Canada, March 15, 1999.
149. UC Davis, Davis, Sacramento, CA, April 14, 1999.
150. Collegeville, Pennsylvania, Visions Symposium, April 27, 1999.
151. Drug Abuse Sciences, Inc., New York, April 29, 1999.
152. University of Missouri-Columbia, April 30, 1999.
153. UCLA Seminar, Los Angeles, CA, May 5, 1999.
154. Hoechst Marion Roussel, Inc. (HMR) New Jersey, June 13, 1999.
155. Novartis (JSC), Basel, Switzerland, June 15, 1999.
156. ACS National Meeting, New Orleans, LA, August 22, 1999.
157. Cal State Fullerton, Department of Chemistry & Biochemistry, September 9, 1999.
158. Lincei Meeting, Rome, Italy, September 15, 1999.
159. Ohio State Fall Seminar Series, Ohio University, Biochemistry Dept., September 28, 1999.

160. Drug Abuse Sciences, Inc., Scientific Advisory Meeting (SAB), October 20, 1999.
161. Inter. Sym. on Molec. Library Technologies at the Millennium, San Francisco, CA, October 24, 1999.
162. The Role of Natural Products in Drug Discovery, Berlin, Germany, November 2, 1999.
163. Comb. Catalysis & Catalyst Opt. (CombiCat 99 Conf.) Philadelphia, PA, November 17, 1999.
164. Frontiers in Bioorganic Chemistry 2000, Taipei, Taiwan, November 29, 1999.
165. Engineered Catalysis Conference (CHI), New Orleans, LA, December 9, 1999.
166. Knowledge Foundation's Comb. Approaches to New Mat. Disc., San Diego, CA, January 23, 2000.
167. Frontiers in Biomedical Research Symposium, Palm Springs, CA, February 14, 2000.
168. Drug Abuse Sciences, Menlo Park, CA, SAB Meeting, February 17, 2000.
169. Bob Bates Retirement Symposium, Univ. of Arizona, Tucson, AZ, April 15, 2000.
170. Drug Abuse Sciences, Menlo Park, CA, SAB Meeting, April 19, 2000.
171. Aventis, Bridgewater, NJ, April 27 - 30, 2000.
172. Yale University, New Haven, CT, May 5, 2000.
173. Pennie & Edmonds, New York, May 17, 2000.
174. CSC 2000 Symposia "Solids & Separation Science in Synthesis", Canada, May 28, 2000.
175. University of Kansas, National Medicinal Symposium, June 13, 2000.
176. Kimball Union Academy, Gordon Conference, July 9-14, 2000.
177. University of Nottingham, London, England, July 11-13, 2000.
178. 2000 Gordon Research Conference on Green Chemistry, Connecticut, July 15-20, 2000.
179. UCSD 3<sup>rd</sup> Annual Combinatorial Chemistry Symposium, July 21, 2000.
180. University of Oklahoma, October 26, 2000.
181. PacificChem 2000, Hawaii, December 14-19, 2000.
182. Cheemspeed, Basel, Switzerland, January 18, 2001.
183. Combinatorial Approaches for New Materials Discovery, January 28-30, 2001.
184. 4<sup>th</sup> Winter Conference on Medicinal and Bio, Steamboat Springs, CO, January 29-February 2, 2001.
185. Frontiers in Biomedical Research Symposium, Palm Springs, CA, February 14, 2001.
186. University of Alabama, Huntsville, AL, March 16, 2001.
187. University of North Carolina, Charlotte, NC, March 19, 2001.
188. 221<sup>st</sup> ACS National Meeting, San Diego, CA, April 1-5, 2001.
189. Wyeth Ayerst, Pearl River site, Newark, NJ, April 9, 2001.
190. Wyeth Ayerst, Princeton, NJ, April 10, 2001.
191. CRP 1<sup>st</sup> Research Symposium, Sacramento, CA, April 19, 2001.
192. 12<sup>th</sup> Conference on Combinatorial Chemistry, Osaka, Japan, April 24, 2001.
193. Fujisawa Company, Osaka, Japan, April 25, 2001.
194. Takeda Pharmaceutical Company, Osaka, Japan, April 26, 2001.
195. Yale Chemical Biology Symposium, New Haven, CT, May 25, 2001.
196. ArQule, Woburn, MA, June 28, 2001.
197. Aventis, Bridgewater, NJ, November 13, 2001.
198. U.C.L.A., School of Medicine, Pharmacology Seminar, Los Angeles, CA, November 14, 2001.

199. TSRI Faculty Lecture Series, La Jolla, CA, January 16, 2002.
200. University of Minnesota Medicinal Chemistry, College of Pharmacy, Minneapolis, MN, April 2, 2002.
201. Carleton University, 32<sup>nd</sup> Spring Synthesis Symposium, Ottawa, Canada, May 7, 2002.
202. 28<sup>th</sup> National Medicinal Chemistry Symposium, Session Chair, San Diego, CA, June 7, 2002.
203. Polymers and Organic Chemistry Conference 2002, Session Chair, San Diego, CA, July 14-18, 2002.
204. University of Hawaii, HI, August 23, 2002.
205. Shire BioChem Lecture, Universite de Montreal, Montreal, Canada, September 10-11, 2002.
206. Rayson Huang Visiting Lecturer, University of Hong Kong, Hong Kong, China, Sep 30-Oct. 4, 2002.
207. Lecture to Faculty, University Wisconsin Milwaukee (UWM), Milwaukee, WI, October 17, 2002.
208. Milwaukee Section ACS / Marquette Dept. of Chem. Faculty, Milwaukee, WI, October 18, 2002.
209. Viikki Biocenter Lecture, Viikki Drug Discovery Tech. Center, Helsinki, Finland, November 11, 2002.
210. Finnish Chemical Congress, Drug Discovery Session, Helsinki, Finland, November 12, 2002.
211. Dept. of Pharmacy, Viikki Drug Discovery Tech. Center, Helsinki, Finland, November 13, 2002.
212. 23<sup>rd</sup> Graduate Student Symposium, Keynote Speaker, Univ. of Michigan, Detroit, MI, March 29, 2003.
213. Graduate Student Org., Invited Speaker, Univ. of North Carolina, Chapel Hill, NC, April 4, 2003.
214. Dept. of Chemistry, Biomolecular Student Seminar, University of Emory, Atlanta, GA, April 14, 2003.
215. Dept. of Chem., Chem. Society Symp. on Combi. Chem., Univ. of Basel, Switzerland, Sept. 12, 2003.
216. Dept. of Chem. & Biochem., Seminaire hors-ville, Univ. of Bern, Switzerland, Sept. 15-17, 2003.
217. BIOPHEX Conference on Cancer & Addiction, San Jose, CA, September 23, 2003.
218. Royal Netherlands Academy of Arts & Sciences, Amsterdam, November 17-19, 2003.
219. Dept. of Metal-Mediated Synthesis, Utrecht University, Utrecht, Netherlands, November 20, 2003.
220. Dept. of Chemistry, Univ. of Texas at San Antonio, San Antonio, Texas, December 1, 2003.
221. Cambridge Healthtech Institute Conference, Keynote Speaker, La Jolla, CA, February 23, 2004.
222. Prolexys Pharmaceuticals, Salt Lake City, UT, May 20, 2004.
223. Botulinum Neurotoxins & Ricin DMID NIAID Investigators Meeting, Bethesda, MD, October 25, 2004.

224. Interagency Botulism Research Coordinating Committee, Baltimore, WA, October 27, 2004.
226. Dept. of Chemistry, Univ. of Hong Kong, Hong Kong, China, December 20, 2004.
227. Dept. of Biomedical Science, Tufts Univ. School of Veterinary Medicine, N. Grafton, MA, March 1, 2005.
228. Alcohol Research Council, Directors Meeting, Plenary Lecturer, La Jolla, CA, March 15, 2005.
229. Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, April 20, 2005.
230. Hoffmann La-Roche, Inc., Nutley, NJ, April 21, 2005.
231. Dept. of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, May 4, 2005.
232. Abbott Laboratories, Abbott Park, IL, July 14, 2005.
233. University of Glasgow, Organon Lecturer, Glasgow, United Kingdom, September 1, 2005.
234. Organon Labs, Motherwell, United Kingdom, September 2, 2005.
235. Dept. of Chemistry, University of Rochester, Rochester, New York, September 21, 2005.
236. National Institute of Health, Bethesda, MD, October 7, 2005.
237. Eisai Co., LLD, Tokyo, Japan, October 17, 2005.
238. Chugai-Roche Pharmaceutical Co., Ltd., Kajiwara, Kamakura-city, Japan, October 18, 2005.
239. Osaka University, Human Life Science Forum, Osaka, Japan, October 19, 2005.
240. Shionogi Pharmaceutical Co., Osaka-city, Japan, October 20, 2005.
241. 2<sup>nd</sup> Annual Immune Epitope Database & Discovery Workshop, Bethesda, Maryland, November 3, 2005.
242. McGill University, Dept. of Chemistry, Montreal, Quebec, Canada, November 8, 2005.
243. Merck Frosst Centre for Therapeutic Res., Montreal, Quebec, Canada, November 9, 2005.
244. Plenary Lecture, Singapore Intl. Chemical Conference, Singapore, December 8, 2005.
245. Chair of 2 meetings, Pacificchem 2005, Oahu, Hawaii, December 15-19, 2005.
246. 2<sup>nd</sup> Botulism Small Molecule Drug Discovery Meeting, Boston, MA, March 15, 2006.
247. Alnylam Pharmaceuticals Lecture, Cambridge, MA, March 16, 2006.
248. Homeland Security Meeting, Frederick, Maryland, March 17, 2006.
249. EISAI London Research Labs, LTD, London, UK, May 30, 2006.
250. Army Medical Research Inst. Of Chem. Defense, Hunt Valley, MD, June 7, 2006.
251. Antibody Engineering Conference, Kagoshima, Japan, June 16, 2006.
252. 9<sup>th</sup> Annual Medchem / Combichem Symposium, San Diego, California, July 21, 2006.
253. Korea Institute for Chemical Technology Symposium, Seoul, Korea, August 25, 2006.
254. Amylin Pharmaceuticals, Inc. San Diego, California, September 29, 2006.
255. Pathogenesis Affinity Group Retreat, Rancho Santa Fe, California, October 11, 2006.
256. Institute of Molecular & Cell Biology, Proteos, Singapore, October 25, 2006.
257. Institute of Bioengineering & Nanotechnology, The Nanos, Singapore, October 26, 2006.
258. The National University of Singapore, Singapore, October 27, 2006.
259. XVth Inter American Conf. on Onchocerciasis, Antigua, Guatemala, November 8, 2006.
260. Botulism Therapy, USAMRIID, Fort Detrich, Maryland, January 12, 2007.
261. Substance Abuse Continuing Education Lecture, California Bar Assoc., January 24, 2007.
262. University of Illinois at Urbana-Champaign, Champaign, Illinois, March 15, 2007.

263. Merck & Co., Inc. Medicinal Chemistry Seminar, Rahway, New Jersey, April 18, 2007.
264. 3<sup>rd</sup> Botulism Small Molecule Drug Development Coordination Meeting, Tufts Cummings School of Veterinary Medicine, Boston, Massachusetts, May 5, 2007.
265. Los Alamos National Laboratories, Bioscience Seminar Speaker, Los Alamos, New Mexico, May 31, 2007.
266. Expert Panel for Ministry of Education, Singapore, June 25-26, 2007.
267. Merial Limited, Duluth, Georgia, July 20, 2007.
268. GlaxoSmithLine Biologicals, Brussels, Belgium, August 20, 2007.
269. Strategies for Engineered Negligible Senescence (SENS) Conference, Queens College, Cambridge England, September 7, 2007.
270. BioJapan 2007 World Business Forum, Yokohama, Japan, September 21, 2007.
271. 57<sup>th</sup> Annual Obesity & Associated Conditions Symposium, Las Vegas, Nevada, September 29, 2007.
272. TRDRP Biennial Conference on Nicotine Vaccines, Sacramento, Calif., October 9, 2007.
273. University of Nebraska, Colloquia Speaker, Lincoln, Nebraska, October 12, 2007.
274. Interagency Botulism Research Coordinating Committee (IBRCC) Meeting, Monterey, California, October 15, 2007.
275. Immune Epitope Database and Discovery Contracts Annual Meeting, La Jolla, California, November 15, 2007.
276. The Chinese University of Hong Kong, Hong Kong, China, April 22, 2008.
277. The City University of Hong Kong, Hong Kong, China, April 23, 2008.
278. The University of Hong Kong, Colloquium Lecture, Hong Kong, China, April 24, 2008.
279. Public Lecture (High School Students), Hong Kong, China, April 25, 2008.
280. The 15<sup>th</sup> Symposium of Chemistry, Keynote Lecture, Hong Kong, China, April 26, 2008.
281. 4<sup>th</sup> Botulism Small Molecule Drug Development Coordination Meeting, Tufts University, North Grafton, Massachusetts, May 5, 2008.
282. Pfizer joint Scientific Meeting, Sandwich, England. May 23, 2008.
283. Toxins 2008 Conference, Baveno, Lake Maggiore, Italy, June 13, 2008.
284. Waseda University Department of Chemistry, Tokyo, Japan, July 3, 2008.
285. Mitsubishi-Tanabe, Tokyo, Japan, July 3, 2008.
286. "Practical Chemical Wisdom" Intl. Symposium, Waseda Univ., Tokyo, Japan, July 4, 2008.
287. Scripps Japan Olympic Year Symposium, Waseda Univ., Tokyo, Japan, July 5, 2008.
288. ACS DOC Symposium on Combinatorial Catalysis and Screening, Philadelphia, Pennsylvania, August 20, 2008.
289. 3<sup>rd</sup> International Conference on Paraoxonases, UCLA, Los Angeles, California, September 9, 2008.
290. Interagency Botulism Research Coordinating Committee (IBRCC), Philadelphia, Pennsylvania, September 17, 2008.
291. IBC's 19<sup>th</sup> Annual Antibody Engineering and Immunotherapeutics Conference, San Diego, California, December 10, 2008.
292. NIH National Cancer Institute, Bethesda, Maryland, January 5, 2009.
293. Frontiers in Biomedical Research Symposium, Indian Wells, California, February 17, 2009.

294. 7<sup>th</sup> ASM Bio-defense and Emerging Diseases Research Meeting, Baltimore, Maryland, February 24, 2009.
295. Immune Epitope Database and Discovery Contracts Annual Meeting, Silver Spring, Maryland, March 10, 2009.
296. Analytical Methods for Distributed Detection Networks Conference, Univ. of Texas, Austin, Texas, March 16, 2009.
297. New York University, New York, New York, March 30, 2009.
298. Frontiers in Science Lecture, California State University, Fullerton, April 15, 2009.
299. 17<sup>th</sup> Annual MSGSA Symposium, Calgary, Alberta – Canada, May 7, 2009.
300. University of Utah, College of Pharmacy, Salt Lake City, Utah, May 21, 2009.
301. 10<sup>th</sup> Tetrahedron Symposium/Tetrahedron Letters 50<sup>th</sup> Anniversary, Paris, France, June 25, 2009.
302. Ben-Gurion University of the Negev, Be'er Sheva, Israel, June 30, 2009.
303. Eli Lilly Distinguished Lecturer for 2009, Organic Division at Colorado State University, Fort Collins, Colorado, July 30-31, 2009.
304. Session Chair for Division of Inorganic Chemistry, 238<sup>th</sup> ACS National Meeting, Washington, D.C., August 18, 2009.
305. American Chemical Society 238<sup>th</sup> National Meeting Lecture, Washington, D.C., August 18, 2009.
306. New England Biolabs, Ipswich, Massachusetts, September 24, 2009.
307. The Interagency Botulism Research Coordinating Committee (IBRCC) 46<sup>th</sup> Annual Meeting, Alexandria, Virginia, October 20, 2009.
308. University of South Carolina, Columbia, South Carolina, November 9, 2009.
309. Medical University of South Carolina, Charleston, South Carolina, November 10, 2009.
310. 48<sup>th</sup> Annual Meeting of American College of Neuropsychopharmacology, Hollywood, Florida, December 9, 2009.
311. University of Utah, Salt Lake City, Utah, February 8, 2010.
312. Scripps Florida, Palm Beach, Florida, April 14, 2010.
313. 2010 Harold A. Iddles Lecturer, University of New Hampshire, Durham, New Hampshire, April 27, 2010.
314. Colorado State University, Dept. of Chemistry, Fort Collins, Colorado, August 5, 2010.
315. Novartis Vaccines & Diagnostics Research Center, Siena, Italy, September 2, 2010.
316. Case Western Reserve University, Cleveland, Ohio, September 16, 2010.
317. University of Kansas, Dept. of Medicinal Chemistry, Lawrence, Kansas, October 1, 2010.
318. University of Nebraska, Dept. of Pathology/Microbiology, McFadden Lecturer, Omaha, Nebraska, October 29, 2010.
319. 47<sup>th</sup> Annual Interagency Botulism Research Coordinating Committee Meeting, Atlanta, Georgia, November 3, 2010.
320. PacificChem 2010 Conference, Honolulu, Hawaii, December 15, 2010.
321. Sanford Center, Sioux Falls, South Dakota, February 9, 2011.
322. Ohio State Biochemistry Program, Columbus, Ohio, March 8, 2011.
323. Colorado State University, Dept. of Chemistry, Fort Collins, Colorado, August 4, 2011.
324. CONNECT Event, AMN Healthcare, San Diego, California, November 22, 2011.
325. Academia Sinica, Taipei, Taiwan, December 13, 2011.

326. St. Jude Children's Research Hospital, Memphis, Tennessee, January 12, 2012.
327. Bayer Pharma AG, Berlin, Germany, January 18, 2012.
328. Pfizer, Cambridge, Massachusetts, January 31, 2012.
329. University of Texas Medical Branch, Sealy Center for Vaccine Development, Cancer Center, Center for Addiction Research and Mitchell Center for Neurodegenerative Diseases, Galveston, Texas, February 8, 2012.
330. New York Academy of Sciences, New York, New York, February 9, 2012.
331. 2012 National Organization for the Professional Advancement of Black Chemists and Chemical Engineers (NOBCChE) West Regional Meeting (at TSRI), La Jolla, California, March 24, 2012.
332. University of Texas at San Antonio Science Center, San Antonio, Texas, March 27, 2012.
333. Poster presentation: Department of Public Health, California Tobacco Control Program (CTCP) and the Tobacco-Related Disease Research Program (TRDRP) at the University of California, Sacramento, California, April 10, 2012.
334. 10<sup>th</sup> Raymond N. Castle Student Research Conference Plenary Lecture, University of Southern Florida, Jacksonville, Florida, April 21, 2012.
335. TEDxEast, New York, New York, May 11, 2012.
336. 13<sup>th</sup> Annual NIH Chemical-Biology Interface Training Grant Symposium, University of Minnesota, Minneapolis, Minnesota, May 17, 2012.
337. 52<sup>nd</sup> Annual NCDEU Panel and Workshop, Phoenix, Arizona, May 31, 2012.
338. 49<sup>TH</sup> Interagency Botulism Research Coordinating Committee (IBRCC), Baltimore, Maryland, September 5, 2012.
339. Skaggs Biomedical Research Symposium, Aurora, Colorado, August 27, 2012.
340. UCSD Drug Discovery Institute Seminar, San Diego, California, November 5, 2012.
341. 13<sup>TH</sup> Tetrahedron Symposium – Asian Edition, Taipei, Taiwan, November 30, 2012.
342. TOXINS 2012: International Neurotoxin Association, Miami Beach, Florida, December 8, 2012.
343. Purdue University, Indianapolis, Indiana, January 28, 2013.
344. 2013 American Society for Microbiology/Dept. of Agriculture Biodefense and Emerging Diseases Research Meeting, Washington, D.C., February 25, 2013.
345. California State University-Long Beach, Long Beach, California, April 24, 2013.
346. Association for Research in Vision & Ophthalmology (ARVO) 2013 Meeting, Seattle, Washington, May 6, 2013.
347. NIDA Biologics Meeting – Division of Pharmacologies and Medical Consequences of Drug Abuse (DPMCDA), Rockville, Maryland, September 12, 2013.
348. Boston University College of Arts and Sciences, Department of Chemistry, Boston, Massachusetts, September 30, 2013.
349. University of Wyoming, Laramie, Wyoming, October 10, 2013.
350. 50<sup>th</sup> Annual Interagency Botulism Research Coordinating Committee (IBRCC), Baltimore, Maryland, October 21, 2013.
351. Pittcon 2014, Technical Program, Chicago, Illinois, March 3, 2014.
352. American Society of Gene & Cell Therapy 17<sup>th</sup> Annual Meeting, Washington, D.C., May 21, 2014.
353. New York World Science Festival, New York, New York, May 30-31, 2014.

354. 2014 L.S. Skaggs Biomedical Research Symposium, Missoula, Montana, August 15, 2014.
355. University of Michigan, College of Pharmacy, September 25, 2014.
356. Temple University, Philadelphia, Pennsylvania, March 19, 2015.
357. Tsinghua University, Beijing, China, July 1, 2015.
358. Peking University, School of Pharmaceutical Sciences, Beijing, China, July 2, 2015.
359. Xingda Lecturer, Peking University, College of Chemistry, Beijing, China, July 3, 2015.
360. Distinguished Seminar Lectureship Speaker, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, September 22, 2015.
361. PacificChem 2015, Honolulu, Hawaii, December 19-20, 2015.
362. Winter Conference on Brain Research, Breckenridge, Colorado, January 28, 2016.
363. 251<sup>st</sup> ACS National Meeting & Exposition – Medicinal Chemistry Symposium, San Diego, California, March 14, 2016.
364. North Carolina State University, Department of Chemistry, Raleigh, North Carolina, March 18, 2016.
365. 2016 American Psychiatric Association Meeting, Atlanta, Georgia, May 15, 2016.
366. 2016 Collaborative + Classy Awards Event, Boston, Massachusetts, June 15, 2016.
367. 2016 Skaggs Biomedical Research Symposium, Pocatello, Idaho, August 4, 2016.
368. 20<sup>th</sup> Anniversary Skaggs Symposium, The Scripps Research Institute, La Jolla, California, September 19, 2016.
369. The University of Kansas, Department of Pharmaceutical Chemistry, Lawrence, Kansas, September 27, 2016.
370. Infectious Diseases and Microbiology Integrated Special Emphasis Panel (IDM-X10), Washington, D.C., November 14, 2016.
371. Nanyang Technological University (NTU), Singapore, January 12, 2017.
372. National University of Singapore (NUS), Singapore, January 13, 2017.
373. 253<sup>rd</sup> American Chemical Society (ACS) National Meeting, Alfred R. Bader Award lecture in Bioinorganic and Biorganic Chemistry, San Francisco, California, April 4, 2017.
374. Clinton Foundaton, Health Matters Annual Activation Summit, Little Rock, Arkansas, April 10, 2017.
375. National Foundation for Infectious Diseases (NFID) 20<sup>th</sup> Annual Conference on Vaccine Research (ACVR), Bethesda, Maryland, April 24, 2017.
377. 254<sup>th</sup> American Chemical Society (ACS) National Meeting, Alfred R. Bader Award lecture in Bioinorganic and Bioorganic Chemistry, Washington, D.C., August 23, 2017.
378. Idaho state University, College of Pharmacy, 2017 Chu Lectureship Award lecture, Meridian, Idaho, October 20, 2017.
379. 2017 Interagency Botulism Research Coordinating Committee (IBRCC) Meeting, San Francisco, California, October 24, 2017.
380. 2017 TSRI Immunology & Microbiology Faculty Retreat, Rancho Valencia, California, November 6, 2017.
381. Defense Threat Reduction Agency (DTRA), Fort Belvoir, Virginia, March 27, 2018.
382. College on Problems of Drug Dependence (CPDD), San Diego, California, June 13, 2018.
383. Moving Targets Symposium, USC Student Chapter of American Association of Pharmaceutical Scientists (AAPS), Los Angeles, California, August 17, 2018.



384. San Diego State University, Dept. of Chemistry and Biochemistry Seminar, San Diego, California, November 30, 2018.
385. Morehouse School of Medicine, Frontiers in Addiction Research and Pregnancy (FrARP) Meeting, Atlanta, Georgia, October 18, 2018.
386. National Institutes of Health (NIAID), lecture to support development of vaccines for the treatment of opioid abuse, Washington, D.C., October 23, 2018.
387. American College of Neuropharmacology (ACNP), Special Panel addressing the Opioid Crisis, Hollywood, Florida, December 13, 2018.
388. TOXINS 2019 Conference, Copenhagen, Denmark, January 18, 2019.
389. Wolk Lecturer, Colgate University, Hamilton, New York, March 26, 2019.
390. Philosophical Society of Washington (PSW), Washington, D.C., April 26, 2019.
400. Beijing University of Chemical Technology, Beijing, China, June 3, 2019.
401. 2019 National Meeting of the American Chemical Society (ACS), Symposium on Waterborne Diseases, San Diego, California August 27, 2019.
402. 2019 National Meeting of the American Chemical Society (ACS), Medicinal Chemistry Division, Portuguese Award Lecture, San Diego, California, August 27, 2019.
403. Uppsala University, Svedberg Seminar Series, Uppsala, Sweden, September 2, 2019.
404. SciLifeLab (Karolinska Institute), Svedberg Seminar Series, Stockholm, Sweden, September 3, 2019.
405. Northwestern University, Department of Pharmacology, Eugene M. Silinsky Student-Led Symposium, Evanston, Illinois, October 7, 2019.
406. 56<sup>th</sup> Interagency Botulism Research Coordinating Committee (IBRCC) Meeting, Ellicott City, Maryland, October 28, 2019.
407. NIDA, Intramural Research Program (IRP) Seminar Series, Baltimore, Maryland, October 29, 2019.
408. University of Kentucky, College of Pharmacy, 10<sup>th</sup> Annual Therapeutics Outcomes Discovery & Delivery (TODD) Symposium, Lexington, Kentucky, November 12, 2019.
409. Tulane University School of Medicine, Department of Microbiology & Immunology, New Orleans, Louisiana, November 18, 2020.
410. University of Minnesota, Pharmaconeuroimmunology Program, Minneapolis, Minnesota, May 3, 2021.
411. NIH Symposium / The Neurosciences: Degenerative Disorders, Neuroplasticity, & Intersection with Glycoscience, Virtual (online), September 9, 2021.
412. Castellan Group Health Care Summit, Cherry Creek, Colorado, September 30, 2021.
413. NIH Director's Wednesday Afternoon Lecture Series (WALS), Virtual (online), November 10, 2021.
414. Pacifichem 2021 – International Chemical Congress of Pacific Basin Societies, Virtual (online), December 21, 2021.
415. Penn-Yale PET Addiction Center of Excellence, Addictions Seminar Series, Virtual (online), March 30, 2023

## Bibliography – Kim D. Janda

---

1. Bates RB, Janda KD. High-yield benzyne synthesis of diaryl ethers. *J Org Chem* **47**(22):4374-6 (1982).
2. Janda KD, McConnell WW, Nelson GO, Wright ME. Preparation and reactivity of the new cyclopentadienyl-bridged complex  $(\text{Me}_2\text{SiCH}_2\text{CH}_2\text{SiMe}_2)(\text{C}_5\text{H}_4\text{Fe}(\text{CO})_2)_2$ . *J Organomet Chem* **259**(2):139-43 (1983).
3. Bates RB, Fletcher FA, Janda KD, Miller WA. A convenient synthesis of unsymmetrical acyclic imides. *J Org Chem* **49**(16):3038 (1984).
4. Bates RB, Gin SL, Hassen MA, Hruby VJ, Janda KD, Kriek GR, Michaud J-P, Vine DB. Synthesis of cyclo-N-methyl-L-tyr-N-methyl-L-tyr-D-ala-L-ala-O,N-dimethyl-L-tyr-L-ala, a cyclic hexapeptide related to the antitumor agent Deoxybouvardin. *Heterocycles* **22**(4):785 - 90 (1984).
5. Bates RB, Janda KD. A convenient synthesis of  $\alpha$ -acylamino alcohols from azlactones. *Synthesis* **1984**(04):310-1 (1984).
6. Bates RB, Janda KD, Wright ME. N-Isobutyrylbenzamide,  $\text{C}_{11}\text{H}_{13}\text{NO}_2$ . *Acta Crystallogr C Struct Chem* **C41**(2):263-4 (1985).
7. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. *Science* **234**(4783):1566-70 (1986). PMID: 3787261.
8. Tramontano A, Janda KD, Lerner RA. Chemical reactivity at an antibody binding site elicited by mechanistic design of a synthetic antigen. *Proc Natl Acad Sci U S A* **83**(18):6736-40 (1986). PMID: 3462723. PMC386584.
9. Tramontano A, Janda K, Napper AD, Benkovic SJ, Lerner RA. Catalytic antibodies. *Cold Spring Harb Symp Quant Biol* **52**:91-6 (1987). PMID: 3454298.
10. Janda KD, Lerner RA, Tramontano A. Antibody catalysis of bimolecular amide formation. *J Am Chem Soc* **110**(14):4835-7 (1988).
11. Janda KD, Schloeder D, Benkovic SJ, Lerner RA. Induction of an antibody that catalyzes the hydrolysis of an amide bond. *Science* **241**(4870):1188-91 (1988). PMID: 3413482.
12. Janda KD, Benkovic SJ, Lerner RA. Catalytic antibodies with lipase activity and R or S substrate selectivity. *Science* **244**(4903):437-40 (1989). PMID: 2717936.
13. Sastry L, Alting-Mees M, Huse WD, Short JM, Sorge JA, Hay BN, Janda KD, Benkovic SJ, Lerner RA. Cloning of the immunological repertoire in *Escherichia coli* for generation of monoclonal catalytic antibodies: Construction of a heavy chain variable region-specific cDNA library. *Proc Natl Acad Sci U S A* **86**(15):5728-32 (1989). PMID: 2503822. PMC297703.
14. Benkovic SJ, Adams JA, Borders CL, Jr., Janda KD, Lerner RA. The enzymic nature of antibody catalysis: Development of multistep kinetic processing. *Science* **250**(4984):1135-9 (1990). PMID: 2251500.
15. Janda KD. New strategies for the design of catalytic antibodies. *Biotechnol Prog* **6**(3):178-81 (1990). PMID: 1366610.
16. Janda KD, Ashley JA. Syntheses of the saturated analogues of 4-nitrophenol and 4-nitroaniline. *Synth Commun* **20**(7):1073-82 (1990).

17. Janda KD, Ashley JA, Jones TM, McLeod DA, Schloeder DM, Weinhouse MI. Immobilized catalytic antibodies in aqueous and organic solvents. *J Am Chem Soc* **112**(24):8886-8 (1990).
18. Janda KD, Weinhouse MI, Schloeder DM, Lerner RA, Benkovic SJ. Bait and switch strategy for obtaining catalytic antibodies with acyl-transfer capabilities. *J Am Chem Soc* **112**(3):1274-5 (1990).
19. Benkovic SJ, Adams J, Janda KD, Lerner RA. A catalytic antibody uses a multistep kinetic sequence. *Ciba Found Symp* **159**:4-12 (1991). PMID: 1959451.
20. Chen YCJ, Hansske F, Janda KD, Robins MJ. Nucleic acid related compounds. 64. Synthesis of 2',3'-diazido-2',3'-dideoxyadenosine and 2',3'-diamino-2',3'-dideoxyadenosine from 9- $\beta$ -D-arabinofuranosyl)adenine. *J Org Chem* **56**(10):3410-3 (1991).
21. Fujii I, Lerner RA, Janda KD. Enantiofacial protonation by catalytic antibodies. *J Am Chem Soc* **113**(22):8528-9 (1991).
22. Harada A, Janda KD, Lerner RA. Abzymes to enzymes. *Kagaku to Kogyo (Japan)* **44**:1108 (1991).
23. Hein MB, Tang Y, McLeod DA, Janda KD, Hiatt A. Evaluation of immunoglobulins from plant cells. *Biotechnol Prog* **7**(5):455-61 (1991). PMID: 1367994.
24. Ikeda S, Weinhouse MI, Janda KD, Lerner RA, Danishefsky SJ. Asymmetric induction via a catalytic antibody. *J Am Chem Soc* **113**(20):7763-4 (1991).
25. Janda KD. Opportunities in organic synthesis for catalytic antibodies. *Proceedings of 15th ABC Symposium, Kyoto, Japan* **3**:63 (1991).
26. Janda KD, Ashley JA, Jones TM, McLeod DA, Schloeder DM, Weinhouse MI, Lerner RA, Gibbs RA, Benkovic PA. Catalytic antibodies with acyl-transfer capabilities: Mechanistic and kinetic investigations. *J Am Chem Soc* **113**(1):291-7 (1991).
27. Janda KD, Benkovic SJ, McLeod DA, Schloeder DM, Lerner RA. Substrate attenuation: An approach to improve antibody catalysis. *Tetrahedron* **47**(14):2503-6 (1991).
28. Janda KD, Weinhouse MI, Danon T, Pacelli KA, Schloeder DM. Antibody bait and switch catalysis: A survey of antigens capable of inducing abzymes with acyl-transfer properties. *J Am Chem Soc* **113**(14):5427-34 (1991).
29. Kang AS, Barbas CF, Janda KD, Benkovic SJ, Lerner RA. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. *Proc Natl Acad Sci U S A* **88**(10):4363-6 (1991). PMID: 1903540. PMC51659.
30. McLeod DA, Brinkworth RI, Ashley JA, Janda KD, Wirsching P. Phosphoramidates and phosphoramidate esters as HIV-1 protease inhibitors. *Bioorg Med Chem Lett* **1**(11):653-8 (1991).
31. Reymond J-L, Janda KD, Lerner RA. Antibody catalysis of glycosidic bond hydrolysis. *Angew Chem Int Ed Engl* **30**(12):1711-3 (1991).
32. Sastry L, Mubarak M, Janda KD, Benkovic SJ, Lerner RA. Screening combinatorial antibody libraries for catalytic acyl transfer reactions. *Ciba Found Symp* **159**:145-51; discussion 51-5 (1991). PMID: 1835693.
33. Wirsching P, Ashley JA, Benkovic SJ, Janda KD, Lerner RA. An unexpectedly efficient catalytic antibody operating by ping-pong and induced fit mechanisms. *Science* **252**(5006):680-5 (1991). PMID: 2024120.

34. Ashley JA, Janda KD. Antibody catalysis in low water content media. *J Org Chem* **57**(25):6691-3 (1992).
35. Chen YCJ, Janda KD. A new approach toward the inhibition of ribonucleases: A water-stable ribonucleoside-technetium chelate. *J Am Chem Soc* **114**(4):1488-9 (1992).
36. Fernholz E, Schloeder D, Liu KKC, Bradshaw CW, Huang H, Janda K, Lerner RA, Wong CH. Specificity of antibody-catalyzed transesterifications using enol esters: A comparison with lipase reactions. *J Org Chem* **57**(17):4756-61 (1992).
37. Gibbs RA, Benkovic PA, Janda KD, Lerner RA, Benkovic SJ. Substituent effects of an antibody-catalyzed hydrolysis of phenyl esters: Further evidence for an acyl-antibody intermediate. *J Am Chem Soc* **114**(9):3528-34 (1992).
38. Ikeda S, Ashley JA, Wirsching P, Janda KD.  $\psi$ [PO<sub>2</sub>-CH<sub>2</sub>N<sup>+</sup>], a new amide bond replacement: Potent, slow-binding inhibition of the HIV protease. *J Am Chem Soc* **114**(19):7604-6 (1992).
39. Reymond JL, Janda KD, Lerner RA. Highly enantioselective protonation catalyzed by an antibody. *J Am Chem Soc* **114**(6):2257-8 (1992).
40. Ashley JA, Lo CHL, McElhaney GP, Wirsching P, Janda KD. Catalytic antibody model for PLP-dependent decarboxylases. *J Am Chem Soc* **115**(6):2515-6 (1993).
41. Chen YCJ, Danon T, Sastry L, Mubarak M, Janda KD, Lerner RA. Catalytic antibodies from combinatorial libraries. *J Am Chem Soc* **115**(1):357-8 (1993).
42. Gouverneur VE, Houk KN, de Pascual-Teresa B, Beno B, Janda KD, Lerner RA. Control of the exo and endo pathways of the Diels-Alder reaction by antibody catalysis. *Science* **262**(5131):204-8 (1993). PMID: 8211138.
43. Ikeda S, Janda KD. Recent development on the research of catalytic antibodies and their applications. *Journal of Synthetic Organic Chemistry (Japan)* **51**(4):284-97 (1993).
44. Janda KD. Catalytic antibodies: The rerouting of chemical reactions. *Biochem Soc Trans* **21**(4):1090-5 (1993). PMID: 8131905.
45. Janda KD. Book review on "Studies in organic chemistry. 46. Biocatalysts in organic synthesis" by J. Halgas. *J Am Chem Soc* **115**(19):8888-9 (1993).
46. Janda KD, Shevlin CG, Lerner RA. Antibody catalysis of a disfavored chemical transformation. *Science* **259**(5094):490-3 (1993). PMID: 8424171.
47. Na J, Houk KN, Shevlin CG, Janda KD, Lerner RA. The energetic advantage of 5-exo versus 6-endo epoxide openings: a preference overwhelmed by antibody catalysis. *J Am Chem Soc* **115**(18):8453-4 (1993). PMID: WOS:A1993LX75200067.
48. Nielsen J, Brenner S, Janda KD. Synthetic methods for the implementation of encoded combinatorial chemistry. *J Am Chem Soc* **115**(21):9812-3 (1993).
49. Wade WS, Ashley JA, Jahangiri GK, McElhaney G, Janda KD, Lerner RA. A highly specific metal-activated catalytic antibody. *J Am Chem Soc* **115**(11):4906-7 (1993).
50. Weinhouse MI, Janda KD. A new methodology for the preparation of vinyl esters. *Synthesis* **1993**(1):81-3 (1993).
51. Cravatt BF, Ashley JA, Janda KD, Boger DL, Lerner RA. Crossing extreme mechanistic barriers by antibody catalysis: Syn elimination to a cis olefin. *J Am Chem Soc* **116**(13):6013-4 (1994).
52. Erb E, Janda KD, Brenner S. Recursive deconvolution of combinatorial chemical libraries. *Proc Natl Acad Sci U S A* **91**(24):11422-6 (1994). PMID: 7972077. PMC45243.

53. Janda KD. Catalytic antibodies and enzyme inhibitors. *Pure & Appl Chem* **66**(4):703-8 (1994).
54. Janda KD. Tagged versus untagged libraries: Methods for the generation and screening of combinatorial chemical libraries. *Proc Natl Acad Sci U S A* **91**(23):10779-85 (1994). PMID: 7971962. PMC45109.
55. Janda KD, Chen Y-CJ. Chemical and biological approaches to catalytic antibodies. In: *Handbook of Experimental Pharmacology: The Pharmacology of Monoclonal Antibodies*. 1st ed. Rosenberg M, Moore GP (ed.). Springer. 1994, p. 209-41.
56. Janda KD, Lo CH, Li T, Barbas CF, 3rd, Wirsching P, Lerner RA. Direct selection for a catalytic mechanism from combinatorial antibody libraries. *Proc Natl Acad Sci U S A* **91**(7):2532-6 (1994). PMID: 8146149. PMC43403.
57. Li T, Janda KD, Ashley JA, Lerner RA. Antibody catalyzed cationic cyclization. *Science* **264**(5163):1289-93 (1994). PMID: 8191282.
58. Nielsen J, Janda KD. Toward chemical implementation of encoded combinatorial libraries. *Methods* **6**(4):361-71 (1994).
59. Shevlin CG, Hilton S, Janda KD. Automation of antibody catalysis: A practical methodology for the use of catalytic antibodies in organic synthesis. *Bioorg Med Chem Lett* **4**(2):297-302 (1994).
60. Yli-Kauhaluoma J, Janda KD. Twisted  $\alpha$ -keto amides as transition-state analogues for acyl-transfer reactions: Synthesis of the immunoconjugates. *Bioorg Med Chem* **2**(6):521-8 (1994). PMID: 7528089.
61. Yli-Kauhaluoma JT, Janda KD. An expedient synthesis of isopropyl anisoles and veratroles. *Tetrahedron Lett* **35**(26):4509-10 (1994).
62. Carrera MR, Ashley JA, Parsons LH, Wirsching P, Koob GF, Janda KD. Suppression of psychoactive effects of cocaine by active immunization. *Nature* **378**(6558):727-30 (1995). PMID: 7501020.
63. Fenniri H, Janda KD, Lerner RA. Encoded reaction cassette for the highly sensitive detection of the making and breaking of chemical bonds. *Proc Natl Acad Sci U S A* **92**(6):2278-82 (1995). PMID: 7892261. PMC42467.
64. Han H, Wolfe MM, Brenner S, Janda KD. Liquid-phase combinatorial synthesis. *Proc Natl Acad Sci U S A* **92**(14):6419-23 (1995). PMID: 7541541. PMC41529.
65. Jain RK, Janda KD, Saltzman WM. Drug discovery and delivery. *Mol Med Today* **1**(1):4 (1995). PMID: 9415129.
66. Janda KD, Shevlin CG, Lerner RA. Oxepane synthesis along a disfavored pathway: The rerouting of a chemical reaction using a catalytic antibody. *J Am Chem Soc* **117**(9):2659-60 (1995).
67. Lavey BJ, Janda KD. Applying antibody catalysis to organic synthesis. In: *Antibody Expression and Engineering (ACS Symposium Series, No. 604)*. 1st ed. Wang HY, Imanaka T (ed.). American Chemical Society. 1995, p. 123.
68. Lerner RA, Janda KD. Catalytic antibodies: Evolution of protein function in real time. In: *Interface between Chemistry and Biochemistry (Experientia Supplementum)*. Jollès P, Jörnvall H (ed.). Birkhäuser Verlag. 1995, p. 121-38.

69. Li T, Hilton S, Janda KD. Remarkable ability of different antibody catalysts to control and diversify the product outcome of cationic cyclization reactions. *J Am Chem Soc* **117**(11):3308-9 (1995).
70. Li T, Hilton S, Janda KD. The potential application of catalytic antibodies to protecting group removal: Catalytic antibodies with broad substrate tolerance. *J Am Chem Soc* **117**(8):2123-7 (1995).
71. Li T, Janda KD. Synthesis of a bifunctional hapten designed to mimic both transition state and to induce "bait and switch" catalysis. *Bioorg Med Chem Lett* **5**(17):2001-4 (1995).
72. Li T, Janda KD, Hilton S, Lerner RA. An antibody-catalyzed nucleophilic substitution reaction at a primary carbon that appears to proceed by an ionization mechanism. *J Am Chem Soc* **117**(8):2367-8 (1995).
73. Rosenblum JS, Lo L-C, Li T, Janda KD, Lerner RA. Antibody-catalyzed phosphate triester hydrolysis. *Angew Chem Int Ed Engl* **34**(20):2275-7 (1995).
74. Wirsching P, Ashley JA, Lo CH, Janda KD, Lerner RA. Reactive immunization. *Science* **270**(5243):1775-82 (1995). PMID: 8525366.
75. Yli-Kauhaluoma JT, Ashley JA, Lo C-H, Tucker L, Wolfe MM, Janda KD. Anti-metallocene antibodies: A new approach to enantioselective catalysis of the Diels-Alder reaction. *J Am Chem Soc* **117**(27):7041-7 (1995).
76. Gravert DJ, Janda KD. Developing small-molecule libraries for drug discovery. *Trends Biotechnol* **14**(4):110-2 (1996). PMID: 8936429.
77. Gravert DJ, Janda KD. Liquid-phase combinatorial synthesis. In: *Molecular Diversity and Combinatorial Chemistry: Libraries and Drug Discovery* (ACS Conference Proceedings). Chaiken IM, Janda KD (ed.). American Chemical Society. 1996, p. 118.
78. Han H, Janda KD. Azatides: Solution and liquid phase syntheses of a new peptidomimetic. *J Am Chem Soc* **118**(11):2539-44 (1996).
79. Han H, Janda KD. Soluble polymer-bound ligand-accelerated catalysis: Asymmetric dihydroxylation. *J Am Chem Soc* **118**(32):7632-3 (1996).
80. Hasserodt J, Janda KD, Lerner RA. Antibody catalyzed terpenoid cyclization. *J Am Chem Soc* **118**(46):11654-5 (1996).
81. Janda KD, Han H. Combinatorial chemistry: A liquid-phase approach. In: *Methods in Enzymology*. Abelson JN (ed.). San Diego/London: Academic Press. 1996, p. 234-47.
82. Janda KD, Shevlin CG, Lo C-HL. Catalytic antibodies: Chemical and biological approaches. In: *Comprehensive Supramolecular Chemistry*. 1st ed. Atwood JL, Davies JED, MacNicol DD, Vögtle F (ed.). Pergamon, New York. 1996, p. 43-72.
83. Jung KW, Janda KD, Sanfilippo PJ, Wachter M. Syntheses and biological evaluation of two new naproxen analogs. *Bioorg Med Chem Lett* **6**(19):2281-2 (1996).
84. Jung KW, Zhao X-y, Janda KD. A linker that allows efficient formation of aliphatic C-H bonds on polymeric supports. *Tetrahedron Lett* **37**(36):6491-4 (1996).
85. Lavey BJ, Janda KD. Antibody catalyzed hydrolysis of a phosphotriester. *Bioorg Med Chem Lett* **6**(13):1523-4 (1996).
86. Lavey BJ, Janda KD. Catalytic antibody mediated hydrolysis of paraoxon. *J Org Chem* **61**(21):7633-6 (1996). PMID: 11667704.
87. Li T, Janda KD, Lerner RA. Cationic cyclopropanation by antibody catalysis. *Nature* **379**(6563):326-7 (1996). PMID: 8552185.

88. Lo C-HL, Gao C, Mao S, Matsui K, Lerner RA, Janda KD. Chain shuffling: Investigations into the specificity and selectivity of antibody catalysis. *Isr J Chem* **36**(2):195-8 (1996).
89. Lo LC, Lo C-HL, Janda KD, Kassel DB, Raushel FM. A versatile mechanism based reaction probe for the direct selection of biocatalysts. *Bioorg Med Chem Lett* **6**(17):2117-20 (1996).
90. Sakurai M, Wirsching P, Janda KD. Synthesis of a nucleoside hapten with a [P(O)-O-N] linkage to elicit catalytic antibodies with phosphodiesterase activity. *Bioorg Med Chem Lett* **6**(9):1055-60 (1996).
91. Sakurai M, Wirsching P, Janda KD. Design and synthesis of a cocaine-diamide hapten for vaccine development. *Tetrahedron Lett* **37**(31):5479-82 (1996).
92. Vandersteen AM, Han H, Janda KD. Liquid-phase combinatorial synthesis: In search of small-molecule enzyme mimics. *Mol Divers* **2**(1-2):89-96 (1996). PMID: 9238638.
93. Vandersteen AM, Janda KD. A re-examination of two linear pentapeptides claimed to be serine protease mimics. *J Am Chem Soc* **118**(37):8787-90 (1996).
94. Wentworth P, Janda KD. A facile and efficient route to 3',5'-diamino-3',5'-dideoxynucleosides. *Chem Commun* (17):2097-8 (1996).
95. Wentworth P, Wiemann T, Janda KD. A new class of pentacoordinate ribonuclease inhibitors: Synthesis, characterization, and inhibition studies of ribonucleoside and anhydropentofuranose oxorhenium(V) complexes. *J Am Chem Soc* **118**(50):12521-7 (1996).
96. Yli-Kauhaluoma JT, Ashley JA, Lo C-HL, Coakley J, Wirsching P, Janda KD. Catalytic antibodies with peptidyl-prolyl cis-trans isomerase activity. *J Am Chem Soc* **118**(23):5496-7 (1996).
97. Yli-Kauhaluoma JT, Janda KD. Catalytic antibodies: The rerouting of chemical reactions. Towards electrophilic aromatic substitution by carbon dioxide. *Ann NY Acad Sci* **799**:26-31 (1996). PMID: 8958069.
98. Chen S, Janda KD. Synthesis of prostaglandin E<sub>2</sub> methyl ester on a soluble-polymer support for the construction of prostanoid libraries. *J Am Chem Soc* **119**(37):8724-5 (1997).
99. Gao C, Lin CH, Lo CH, Mao S, Wirsching P, Lerner RA, Janda KD. Making chemistry selectable by linking it to infectivity. *Proc Natl Acad Sci U S A* **94**(22):11777-82 (1997). PMID: 9342313. PMC23570.
100. Gravert DJ, Janda KD. Organic synthesis on soluble polymer supports: Liquid-phase methodologies. *Chem Rev* **97**(2):489-510 (1997). PMID: 11848880.
101. Gravert DJ, Janda KD. Soluble polyethylene glycol supports for liquid-phase combinatorial synthesis. *Drugs of the Future* **22**(10):1147-50 (1997).
102. Gravert DJ, Janda KD. Synthesis on soluble polymers: New reactions and the construction of small molecules. *Curr Opin Chem Biol* **1**(1):107-13 (1997). PMID: 9667833.
103. Han H, Janda KD. A soluble polymer-bound approach to the Sharpless catalytic asymmetric dihydroxylation (AD) reaction: Preparation and application of a [(DHQD)2PHAL-PEG-OMe] ligand. *Tetrahedron Lett* **38**(9):1527-30 (1997).
104. Han H, Janda KD. Multipolymer-supported substrate and ligand approach to the Sharpless asymmetric dihydroxylation. *Angew Chem Int Ed Engl* **36**(16):1731-3 (1997).

105. Hasserodt J, Janda KD. Syntheses of octahydroquinoline-N-oxides: Haptens designed to elicit catalytic antibodies that control a terpenoid-like cascade cyclisation. *Tetrahedron* **53**(33):11237-56 (1997).
106. Hasserodt J, Janda KD, Lerner RA. Formation of bridge-methylated decalins by antibody-catalyzed tandem cationic cyclization. *J Am Chem Soc* **119**(26):5993-8 (1997).
107. Janda KD. Book review on "Combinatorial Peptide and Nonpeptide Libraries. A Handbook", edited by G. Jung. *J Am Chem Soc* **119**(16):3848- (1997).
108. Janda KD, Gravert DJ. Organic reactions on soluble polymer supports as an alternative methodology for combinatorial solid-phase synthesis. *Biotechnology International* **169** (1997).
109. Janda KD, Lo LC, Lo CH, Sim MM, Wang R, Wong CH, Lerner RA. Chemical selection for catalysis in combinatorial antibody libraries. *Science* **275**(5302):945-8 (1997). PMID: 9020070.
110. Jung KW, Zhao X-y, Janda KD. Development of new linkers for the formation of aliphatic C-H bonds on polymeric supports. *Tetrahedron* **53**(19):6645-52 (1997).
111. Li T, Lerner RA, Janda KD. Antibody-catalyzed cationic reactions: Rerouting of chemical transformations via antibody catalysis. *Acc Chem Res* **30**(3):115-21 (1997).
112. Lin CH, Hoffman TZ, Wirsching P, Barbas CF, 3rd, Janda KD, Lerner RA. On roads not taken in the evolution of protein catalysts: Antibody steroid isomerases that use an enamine mechanism. *Proc Natl Acad Sci U S A* **94**(22):11773-6 (1997). PMID: 9342312. PMC23568.
113. Lo C-HL, Wentworth P, Jung KW, Yoon J, Ashley JA, Janda KD. Reactive immunization strategy generates antibodies with high catalytic proficiencies. *J Am Chem Soc* **119**(42):10251-2 (1997).
114. Weiner DP, Wiemann T, Wolfe MM, Wentworth P, Janda KD. A pentacoordinate oxorhenium(V) metallochelate elicits antibody catalysts for phosphodiester cleavage. *J Am Chem Soc* **119**(17):4088-9 (1997).
115. Wentworth Jr P, Janda KD. Synthesis of oxorhenium (V) and oxotechnetium (V) complexes as inhibitors of ribonucleases and for the generation of catalytic antibodies. *Synlett* **1997**(05):537-43 (1997).
116. Wentworth Jr P, M. Vandersteen A, D. Janda K. Poly(ethylene glycol) (PEG) as a reagent support: The preparation and utility of a PEG-triarylphosphine conjugate in liquid-phase organic synthesis (LPOS). *Chem Commun* (8):759-60 (1997).
117. Zhao X-y, Janda KD. Syntheses of alkylated malonates on a traceless linker derived soluble polymer support. *Tetrahedron Lett* **38**(31):5437-40 (1997).
118. Zhao X-y, Jung KW, Janda KD. Soluble polymer synthesis: An improved traceless linker methodology for aliphatic C-H bond formation. *Tetrahedron Lett* **38**(6):977-80 (1997).
119. Berg T, Vandersteen AM, Janda KD. High-throughput synthesis and direct screening for the discovery of novel hydrolytic metal complexes. *Bioorg Med Chem Lett* **8**(10):1221-4 (1998). PMID: 9871739.
120. Chen S, Janda KD. Total synthesis of naturally occurring prostaglandin F2 $\alpha$  on a non-cross-linked polystyrene support. *Tetrahedron Lett* **39**(23):3943-6 (1998).
121. Gao C, Lavey BJ, Lo C-HL, Datta A, Wentworth P, Janda KD. Direct selection for catalysis from combinatorial antibody libraries using a boronic acid probe: Primary amide bond hydrolysis. *J Am Chem Soc* **120**(10):2211-7 (1998).



122. Gravert DJ, Datta A, Wentworth P, Janda KD. Soluble supports tailored for organic synthesis: Parallel polymer synthesis via sequential normal/living free radical processes. *J Am Chem Soc* **120**(37):9481-95 (1998).
123. Gravert DJ, Janda KD. Bifunctional initiators for free radical polymerization of non-crosslinked block copolymers. *Tetrahedron Lett* **39**(12):1513-6 (1998).
124. Han H, Yoon J, Janda KD. Investigations of azapeptides as mimetics of Leu-enkephalin. *Bioorg Med Chem Lett* **8**(1):117-20 (1998). PMID: 9871637.
125. Han H, Yoon J, Janda KD. An efficient asymmetric route to 2,3-ciaminobutanoic acids. *J Org Chem* **63**(6):2045-8 (1998).
126. Heine A, Stura EA, Yli-Kauhaluoma JT, Gao C, Deng Q, Beno BR, Houk KN, Janda KD, Wilson IA. An antibody exo Diels-Alderase inhibitor complex at 1.95 angstrom resolution. *Science* **279**(5358):1934-40 (1998). PMID: 9506943.
127. Hori M, Gravert DJ, Wentworth P, Jr., Janda KD. Investigating highly crosslinked macroporous resins for solid-phase synthesis. *Bioorg Med Chem Lett* **8**(17):2363-8 (1998). PMID: 9873542.
128. Hori M, Janda KD. A soluble polymer approach to the "fishing out" principle: Synthesis and purification of  $\beta$ -amino alcohols. *J Org Chem* **63**(3):889-94 (1998). PMID: 11672090.
129. Lerner RA, Barbas CF, 3rd, Janda KD. Making enzymes. In: The Harvey Lectures 1996-1997. Folkman J, Goeddel DV, Hogan BLM, Hood L, Klausner RD, Lerner RA, et al. (ed.). Wiley-Liss. 1998, p. 1-40.
130. Lin C-H, Z. Hoffman T, Xie Y. An antibody transesterase derived from reactive immunization that utilizes a wide variety of alcohol substrates. *Chem Commun* (10):1075-6 (1998).
131. Taylor MJ, Hoffman TZ, Yli-Kauhaluoma JT, Lerner RA, Janda KD. A light-activated antibody catalyst. *J Am Chem Soc* **120**(49):12783-90 (1998).
132. Wentworth P, Janda KD. Generating and analyzing combinatorial chemistry libraries. *Curr Opin Biotechnol* **9**(1):109-15 (1998).
133. Wentworth P, Janda KD. Catalytic antibodies. *Curr Opin Chem Biol* **2**(1):138-44 (1998). PMID: 9667908.
134. Wentworth P, Jr., Liu Y, Wentworth AD, Fan P, Foley MJ, Janda KD. A bait and switch hapten strategy generates catalytic antibodies for phosphodiester hydrolysis. *Proc Natl Acad Sci U S A* **95**(11):5971-5 (1998). PMID: 9600901. PMC27569.
135. Yli-Kauhaluoma JT, Harwig CW, Wentworth P, Janda KD. Unexpected 1,3-oxazolidine formation in the attempted oxidation of N-aryl-N-methyl substituted  $\beta$ -amino alcohols using pyridinium dichromate. *Tetrahedron Lett* **39**(16):2269-72 (1998).
136. Yoon J, Cho C-W, Han H, D. Janda K. Solution and soluble polymer syntheses of 3-aminoimidazoline-2,4-diones. *Chem Commun* (24):2703-4 (1998).
137. Zhao X-Y, Metz WA, Sieber F, Janda KD. Expanding on the purification methodology of polyethylene glycol (PEG) bound molecules: The synthesis of 3,5-pyrazolidinediones. *Tetrahedron Lett* **39**(46):8433-6 (1998).
138. Zhao XY, Janda KD. Soluble polymer traceless linker investigations: Solvent effects on the desulfonylation of polyethylene glycol (PEG) substituted aryl alkyl sulfones with sodium amalgam. *Bioorg Med Chem Lett* **8**(18):2439-42 (1998). PMID: 9873557.

139. Ashley JA, Lin CH, Wirsching P, Janda KD. Monitoring chemical warfare agents: A new method for the detection of methylphosphonic acid. *Angew Chem Int Ed Engl* **38**(12):1793-5 (1999). PMID: 29711182.
140. Berg T, Simeonov A, Janda KD. A combined parallel synthesis and screening of macrocyclic lanthanide complexes for the cleavage of phospho di- and triesters and double-stranded DNA. *J Comb Chem* **1**(1):96-100 (1999). PMID: 10746017.
141. Brümmer O, Gao C, Mao S, Weiner DP, Janda KD. Design, synthesis and characterization of panning agents for the selection of metalloantibodies. *Lett Pept Sci* **6**(5-6):295-302 (1999).
142. Brümmer O, La Clair JJ, Janda KD. A colorimetric ligand for mercuric ion. *Org Lett* **1**(3):415-8 (1999).
143. Brümmer O, Wentworth P, Weiner DP, Janda KD. Phosphorodithioates: Synthesis and evaluation of new haptens for the generation of antibody acyl transferases. *Tetrahedron Lett* **40**(41):7307-10 (1999).
144. Córdova A, Reed NN, Ashley JA, Janda KD. Convenient synthesis of L-proline benzyl ester. *Bioorg Med Chem Lett* **9**(21):3119-22 (1999). PMID: 10560736.
145. Datta A, Wentworth P, Shaw JP, Simeonov A, Janda KD. Catalytically distinct antibodies prepared by the reactive immunization versus transition state analogue hapten manifolds. *J Am Chem Soc* **121**(45):10461-7 (1999).
146. Gao C, Brümmer O, Mao S, Janda KD. Selection of human metalloantibodies from a combinatorial phage single-chain antibody library. *J Am Chem Soc* **121**(27):6517-8 (1999).
147. Gao C, Mao S, Lo CH, Wirsching P, Lerner RA, Janda KD. Making artificial antibodies: A format for phage display of combinatorial heterodimeric arrays. *Proc Natl Acad Sci U S A* **96**(11):6025-30 (1999). PMID: 10339535. PMC26829.
148. Garibay PW, Toy PH, Hoeg-Jensen T, Janda KD. Application of a new solid-phase resin: Benzamide *ortho*-lithiation and the synthesis of a phthalide library. *Synlett* **1999**:1438-40 (1999).
149. Han H, Cho C-W, Janda KD. A substrate-based methodology that allows the regioselective control of the catalytic aminohydroxylation reaction. *Chemistry: A European Journal* **5**:1565-9 (1999).
150. Han H, Vandersteen A, Janda KD. Combinatorics, peptide mimetics and combizymes. In: *Peptides: Frontiers of Peptide Science (Proceedings of the 15th American Peptide Symposium)*. Tam JP, Kaumaya PTP (ed.). Nashville, TN: Kluwer/Escom. 1999, p. 22-4.
151. Han H, Yoon J, Janda KD. Azatides as peptidomimetics: Solution and liquid phase syntheses. In: *Peptidomimetics Protocols*. Kazmierski WM (ed.). Totowa, N.J.: Humana Press, Inc. 1999, p. 87-102.
152. Harwig CW, Gravert DJ, Janda KD. Soluble polymers: New options in both traditional and combinatorial synthesis. *Chemtracts Organic Chemistry* **12**:1-26 (1999).
153. Janda KD, Wentworth AD. A merging of chemistry and biology in terms of antibody catalysis. *Phosphorus, Sulfur, and Silicon and the Related Elements* **144**(1):117-20 (1999).
154. Lee KJ, Angulo A, Ghazal P, Janda KD. Soluble-polymer supported synthesis of a prostanoid library: Identification of antiviral activity. *Org Lett* **1**(11):1859-62 (1999). PMID: 10836045.

155. Mao S, Gao C, Lo CH, Wirsching P, Wong CH, Janda KD. Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. *Proc Natl Acad Sci U S A* **96**(12):6953-8 (1999). PMID: 10359820. PMC22023.
156. Paschall CM, Hasserodt J, Jones T, Lerner RA, Janda KD, Christianson DW. Convergence of catalytic antibody and terpene cyclase mechanisms: Polyene cyclization directed by carbocation- $\pi$  Interaction. *Angew Chem Int Ed Engl* **38**(12):1743-7 (1999). PMID: 29711206.
157. Sieber F, Wentworth P, Jr., Janda KD. Exploring the scope of poly(ethylene glycol) (PEG) as a soluble polymer matrix for the Stille cross-coupling reaction. *J Comb Chem* **1**(6):540-6 (1999). PMID: 10748731.
158. Sieber F, Wentworth P, Toker JD, Wentworth AD, Metz WA, Reed NN, Janda KD. Development and application of a poly(ethylene glycol)-supported triarylphosphine reagent: Expanding the sphere of liquid-phase organic synthesis. *J Org Chem* **64**(14):5188-92 (1999). PMID: 34237880.
159. Spivak DA, Hoffman TZ, Moore AH, Taylor MJ, Janda KD. A comparison of flexible and constrained haptens in eliciting antibody catalysts for paraoxon hydrolysis. *Bioorg Med Chem* **7**(6):1145-50 (1999). PMID: 10428386.
160. Taylor MJ, Yli-Kauhaluoma JT, Ashley JA, Wirsching P, Lerner RA, Janda KD. The  $\alpha$ -ketoamide group: A new motif for the elicitation of catalytic antibodies for acyl-transfer reactions. *J Chem Soc, Perkin Trans 1* (9):1133-4 (1999).
161. Toy PH, Janda KD. New supports for solid-phase organic synthesis: Development of polystyrene resins containing tetrahydrofuran derived cross-linkers. *Tetrahedron Lett* **40**(35):6329-32 (1999).
162. Wentworth Jr P, D. Janda K. Liquid-phase chemistry: Recent advances in soluble polymer-supported catalysts, reagents and synthesis. *Chem Commun* (19):1917-24 (1999).
163. Wentworth P, Janda KD. Antibody catalysis of phosphodiester hydrolysis: A survey of hapten strategies. *Phosphorus, Sulfur, and Silicon and the Related Elements* **144**(1):247-50 (1999).
164. Wentworth P, Jr., Janda KD. Catalytic antibodies. In: *Comprehensive Asymmetric Catalysis*. Jacobsen EN, Pfaltz A, Yamamoto H (ed.). New York: Springer-Verlag. 1999, p. 1403-22.
165. Yoon J, Han H, Janda KD. Solution and soluble polymer syntheses of azatides and azapeptides. In: *Advances in Amino Acid Mimetics and Peptidomimetics*. Abell A (ed.). Stamford, CT: JAI Press, Inc. 1999, p. 247-62.
166. Brümmer O, Clapham B, Janda KD. Recent developments and applications of polymer-supported reagents in synthetic organic chemistry. *Curr Opin Drug Discov Devel* **3**(4):462-73 (2000). PMID: 19649877.
167. Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. Cocaine vaccines: Antibody protection against relapse in a rat model. *Proc Natl Acad Sci USA* **97**(11):6202-6 (2000). PMID: 10823960. PMC18582.
168. Harwig CW, Hoffman TZ, Wentworth AD, Janda KD. A one-pot multistep approach to alpha-azido-phosphonate and phosphonothioate diesters: Key intermediates in the

- synthesis of haptens for the generation of antibody ligases. *Bioorg Med Chem Lett* **10**(9):915-8 (2000). PMID: 10853659.
169. Hasserodt J, Janda KD, Lerner RA. A class of 4-aza-lithocholic acid-derived haptens for the generation of catalytic antibodies with steroid synthase capabilities. *Bioorg Med Chem* **8**(5):995-1003 (2000). PMID: 10882011.
  170. Hasserodt J, Janda KD, Lerner RA. Antibodies mimic natural oxidosqualene-cyclase action in steroid ring a formation. *J Am Chem Soc* **122**(1):40-5 (2000).
  171. Janda KD. New directions in immunopharmacotherapy. In: *The Role of Natural Products in Drug Discovery* (Ernst Schering Research Foundation Workshop 32). 2000/11/15 ed. Mulzer J, Bohlmann R (ed.). Berlin, Heidelberg: Springer Verlag. 2000, p. 315-46.
  172. Lopez-Pelegrin JA, Janda KD. Solution- and soluble-polymer supported asymmetric syntheses of six-membered ring prostanoids. *Chem Eur J* **6**(11):1917-22 (2000). PMID: 10894390.
  173. Lopez-Pelegrin JA, Wentworth P, Jr., Sieber F, Metz WA, Janda KD. Soluble polymer-supported chemoenzymatic synthesis of the C<sub>21</sub>-C<sub>27</sub> fragment of the bryostatins. *J Org Chem* **65**(25):8527-31 (2000). PMID: 11112572.
  174. Manzotti R, Janda KD. Solid and liquid phase chemistry: Development of new supports for solid phase organic synthesis and for liquid phase chemistry. *Chimica Oggi - Chemistry Today* **18**(7-8):14-8 (2000).
  175. Manzotti R, Reger TS, Janda KD. Improved synthesis of (4-ethenylphenyl)diphenyl methanol and its application in the preparation of trityl functionalized polystyrene resin containing tetrahydrofuran derived cross-linker. *Tetrahedron Lett* **41**(44):8417-20 (2000).
  176. Manzotti R, Tang S-Y, Janda KD. Improved synthesis of prostanoids on a non-cross-linked polystyrene soluble support. *Tetrahedron* **56**(40):7885-92 (2000).
  177. Reed NN, Janda KD. Stealth star polymers: A new high-loading scaffold for liquid-phase organic synthesis. *Org Lett* **2**(9):1311-3 (2000). PMID: 10810735.
  178. Reed NN, Janda KD. A one-step synthesis of monoprotected polyethylene glycol ethers. *J Org Chem* **65**(18):5843-5 (2000). PMID: 10970334.
  179. Reger TS, Janda KD. Polymer-supported (salen)Mn catalysts for asymmetric epoxidation: A comparison between soluble and insoluble matrices. *J Am Chem Soc* **122**(29):6929-34 (2000).
  180. Sieber F, Wentworth P, Janda KD. Exploiting poly(ethylene glycol) as a matrix for liquid-phase organic synthesis. *Molecules* **5**(8):1018-32 (2000).
  181. Simeonov A, Matsushita M, Juban EA, Thompson EH, Hoffman TZ, Beuscher AEt, Taylor MJ, Wirsching P, Rettig W, McCusker JK, Stevens RC, Millar DP, Schultz PG, Lerner RA, Janda KD. Blue-fluorescent antibodies. *Science* **290**(5490):307-13 (2000). PMID: 11030644.
  182. Toker JD, Wentworth P, Hu Y, Houk KN, Janda KD. Antibody-catalysis of a bimolecular asymmetric 1,3-dipolar cycloaddition reaction. *J Am Chem Soc* **122**(13):3244-5 (2000).
  183. Toy PH, Janda KD. Soluble polymer-supported organic synthesis. *Acc Chem Res* **33**(8):546-54 (2000). PMID: 10955985.
  184. Toy PH, Reger TS, Janda KD. Tailoring polystyrene solid-phase synthesis resins: Incorporation of flexible cross-linkers. *Aldrichimica Acta* **33**(3):87-93 (2000).

185. Toy PH, Reger TS, Janda KD. Soluble polymer bound cleavage reagents: A multipolymer strategy for the cleavage of tertiary amines from REM resin. *Org Lett* **2**(15):2205-7 (2000). PMID: 10930244.
186. Tremblay MR, Wentworth P, Jr., Lee GE, Jr., Janda KD. Parallel solid-phase synthesis and structural characterization of a library of highly substituted chiral 1,3-oxazolidines. *J Comb Chem* **2**(6):698-709 (2000). PMID: 11126298.
187. Vaino AR, Goodin DB, Janda KD. Investigating resins for solid phase organic synthesis: The relationship between swelling and microenvironment as probed by EPR and fluorescence spectroscopy. *J Comb Chem* **2**(4):330-6 (2000). PMID: 10891099.
188. Vaino AR, Janda KD. Solid-phase organic synthesis: A critical understanding of the resin. *J Comb Chem* **2**(6):579-96 (2000). PMID: 11126287.
189. Vaino AR, Janda KD. Euclidean shape-encoded combinatorial chemical libraries. *Proc Natl Acad Sci U S A* **97**(14):7692-6 (2000). PMID: 10884401. PMC16605.
190. Wentworth AD, Jones LH, Wentworth P, Jr., Janda KD, Lerner RA. Antibodies have the intrinsic capacity to destroy antigens. *Proc Natl Acad Sci U S A* **97**(20):10930-5 (2000). PMID: 11005865. PMC27126.
191. Wentworth AD, Wentworth P, Jr., Mansoor UF, Janda KD. A soluble polymer-supported triflating reagent: A high-throughput synthetic approach to aryl and enol triflates. *Org Lett* **2**(4):477-80 (2000). PMID: 10814355.
192. Wentworth P, Jr., Janda KD, editors. A tool-box of polymer matrices for the combinatorial chemist / biotechnologist. International Convention on Agriculture, Biotechnology and Chemistry; 2000; Rome, Italy.
193. Brümmer O, Clapham B, Janda KD. Solid-phase synthesis of oligoesters using a JandaJel™ resin. *Tetrahedron Lett* **42**(12):2257-9 (2001).
194. Brümmer O, Hoffman TZ, Janda KD. Metalloantibodies: Mercury(II)-dependent acyl transferases. *Bioorg Med Chem* **9**(9):2253-7 (2001). PMID: 11553463.
195. Brümmer O, La Clair JJ, Janda KD. Practical screening of mercury contamination in fish tissue. *Bioorg Med Chem* **9**(4):1067-71 (2001). PMID: 11354663.
196. Brümmer O, Hoffman TZ, Chen D-W, Janda KD. Antibody-catalyzed hydrolysis of oligomeric esters: A model for the degradation of polymeric materials. *Chem Commun* **1**:19-20 (2001).
197. Carrera MR, Ashley JA, Wirsching P, Koob GF, Janda KD. A second-generation vaccine protects against the psychoactive effects of cocaine. *Proc Natl Acad Sci U S A* **98**(4):1988-92 (2001). PMID: 11172063. PMC29369.
198. Chen D-W, Kubiak RJ, Ashley JA, Janda KD. Reactive immunization elicits catalytic antibodies for polyester hydrolysis. *J Chem Soc, Perkin Trans 1* (21):2796-803 (2001).
199. Chen DW, Beuscher AEt, Stevens RC, Wirsching P, Lerner RA, Janda KD. Preparation of stilbene-tethered nonnatural nucleosides for use with blue-fluorescent antibodies. *J Org Chem* **66**(5):1725-32 (2001). PMID: 11262119.
200. Clapham B, Cho CW, Janda KD. A polymer-supported proline-based diamine catalyst for the kinetic resolution of racemic secondary alcohols. *J Org Chem* **66**(3):868-73 (2001). PMID: 11430106.
201. Clapham B, Reger TS, Janda KD. Polymer-supported catalysis in synthetic organic chemistry. *Tetrahedron* **57**(22):4637-62 (2001).

202. Clapham B, Spanka C, Janda KD. Solid-phase rhodium carbenoid reactions: An N-H insertion route to a diverse series of oxazoles. *Org Lett* **3**(14):2173-6 (2001). PMID: 11440572.
203. Córdova A, Janda KD. Synthesis and catalytic antibody functionalization of dendrimers. *J Am Chem Soc* **123**(34):8248-59 (2001). PMID: 11516276.
204. Córdova A, Janda KD. A highly chemo- and stereoselective synthesis of  $\beta$ -keto esters via a polymer-supported lipase catalyzed transesterification. *J Org Chem* **66**(5):1906-9 (2001). PMID: 11262145.
205. Córdova A, Tremblay MR, Clapham B, Janda KD. A sequential application of kinetic resolution and polymer-supported scavenging for the isolation of chiral secondary alcohols. *J Org Chem* **66**(16):5645-8 (2001). PMID: 11485501.
206. Dickerson TJ, Reed NN, Janda KD. Regio-reactive resin: A platform for orthogonal loading using the polymer backbone and cross-linker. *Bioorg Med Chem Lett* **11**(12):1507-9 (2001). PMID: 11412970.
207. Isomura S, Wirsching P, Janda KD. An immunotherapeutic program for the treatment of nicotine addiction: Hapten design and synthesis. *J Org Chem* **66**(12):4115-21 (2001). PMID: 11397142.
208. Jones LH, Harwig CW, Wentworth P, Jr., Simeonov A, Wentworth AD, Py S, Ashley JA, Lerner RA, Janda KD. Conversion of enediynes into quinones by antibody catalysis and in aqueous buffers: Implications for an alternative enediyne therapeutic mechanism. *J Am Chem Soc* **123**(15):3607-8 (2001). PMID: 11472138.
209. Kozlov IA, Mao S, Xu Y, Huang X, Lee L, Sears PS, Gao C, Coyle AR, Janda KD, Wong CH. Synthesis of solid-supported mirror-image sugars: A novel method for selecting receptors for cellular-surface carbohydrates. *ChemBioChem* **2**(10):741-6 (2001). PMID: 11948856.
210. Larsen NA, Zhou B, Heine A, Wirsching P, Janda KD, Wilson IA. Crystal structure of a cocaine-binding antibody. *J Mol Biol* **311**(1):9-15 (2001). PMID: 11469854.
211. Lee KJ, Janda KD. Traceless solid-phase synthesis of 5-benzoylbenzimidazoles. *Can J Chem* **79**(11):1556-61 (2001).
212. Matsushita M, Hoffman TZ, Ashley JA, Zhou B, Wirsching P, Janda KD. Cocaine catalytic antibodies: The primary importance of linker effects. *Bioorg Med Chem Lett* **11**(2):87-90 (2001). PMID: 11206477.
213. Toy PH, Reger TS, Garibay P, Garno JC, Malikayil JA, Liu G, Janda KD. Polytetrahydrofuran cross-linked polystyrene resins for solid-phase organic synthesis. *J Comb Chem* **3**(1):117-24 (2001). PMID: 11148072.
214. Tremblay Martin R, Dickerson Tobin J, Janda Kim D. Advances in antibody catalysis of cycloaddition reactions. *Adv Synth Catal* **343**(6-7):577-85 (2001).
215. Wen K, Han H, Hoffman TZ, Janda KD, Orgel LE. The synthesis of  $\beta$ -peptides containing guanidino groups. *Bioorg Med Chem Lett* **11**(5):689-91 (2001). PMID: 11266170.
216. Wentworth P, Jr., Janda KD. Catalytic antibodies: Structure and function. *Cell Biochem Biophys* **35**(1):63-87 (2001). PMID: 11898856.
217. Wentworth P, Jr., Jones LH, Wentworth AD, Zhu X, Larsen NA, Wilson IA, Xu X, Goddard WA, 3rd, Janda KD, Eschenmoser A, Lerner RA. Antibody catalysis of the oxidation of water. *Science* **293**(5536):1806-11 (2001). PMID: 11546867.

218. Ahn JM, Boyle NA, MacDonald MT, Janda KD. Peptidomimetics and peptide backbone modifications. *Mini Rev Med Chem* **2**(5):463-73 (2002). PMID: 12370047.
219. Boyle NA, Janda KD. Formats for combinatorial synthesis: Solid-phase, liquid-phase and surface. *Curr Opin Chem Biol* **6**(3):339-46 (2002). PMID: 12023115.
220. Clapham B, Lee S-H, Koch G, Zimmermann J, Janda KD. The preparation of polymer bound  $\beta$ -ketoesters and their conversion into an array of oxazoles. *Tetrahedron Lett* **43**(31):5407-10 (2002).
221. Delgado M, Janda KD. Polymeric supports for solid phase organic synthesis. *Curr Org Chem* **6**(12):1031-43 (2002).
222. Delgado M, Lee KJ, Altobelli L, 3rd, Spanka C, Wentworth P, Jr., Janda KD. A parallel approach to the discovery of carrier delivery vehicles to enhance antigen immunogenicity. *J Am Chem Soc* **124**(18):4946-7 (2002). PMID: 11982344.
223. Delgado M, Spanka C, Kerwin LD, Wentworth P, Jr., Janda KD. A tunable hydrogel for encapsulation and controlled release of bioactive proteins. *Biomacromolecules* **3**(2):262-71 (2002). PMID: 11888310.
224. Dickerson T, Córdova A, Chen D-W, Janda KD. The use of enzymes and catalytic antibodies in the asymmetric aldol reaction. In: Encyclopedia of Catalysis. 1st ed. Horvath IT (ed.). New York: Wiley. 2002.
225. Dickerson TJ, Janda KD. Aqueous aldol catalysis by a nicotine metabolite. *J Am Chem Soc* **124**(13):3220-1 (2002). PMID: 11916401.
226. Dickerson TJ, Janda KD. A previously undescribed chemical link between smoking and metabolic disease. *Proc Natl Acad Sci U S A* **99**(23):15084-8 (2002). PMID: 12403823. PMC137547.
227. Dickerson TJ, Reed NN, Janda KD. Soluble polymers as scaffolds for recoverable catalysts and reagents. *Chem Rev* **102**(10):3325-44 (2002). PMID: 12371887.
228. Gao C, Mao S, Ditzel HJ, Farnes L, Wirsching P, Lerner RA, Janda KD. A cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library. *Bioorg Med Chem* **10**(12):4057-65 (2002). PMID: 12413859.
229. Gao C, Mao S, Kaufmann G, Wirsching P, Lerner RA, Janda KD. A method for the generation of combinatorial antibody libraries using pIX phage display. *Proc Natl Acad Sci U S A* **99**(20):12612-6 (2002). PMID: 12239343. PMC130508.
230. Isomura S, Ashley JA, Wirsching P, Janda KD. Antibody-catalyzed cleavage of the D-Ala-D-Lac depsipeptide: An immunological approach to the problem of vancomycin resistance. *Bioorg Med Chem Lett* **12**(6):861-4 (2002). PMID: 11958980.
231. Isomura S, Hoffman TZ, Wirsching P, Janda KD. Synthesis, properties, and reactivity of cocaine benzoylthio ester possessing the cocaine absolute configuration. *J Am Chem Soc* **124**(14):3661-8 (2002). PMID: 11929256.
232. Janda K. Polymer supported catalysts and reagents in synthetic organic chemistry. *Bioorg Med Chem Lett* **12**(14):viii (2002).
233. Jones LH, Altobelli LJ, 3rd, MacDonald MT, Boyle NA, Wentworth P, Jr., Lerner RA, Janda KD. Active immunization with a glycolipid transition state analogue protects against endotoxic shock. *Angew Chem Int Ed Engl* **41**(22):4241-4 (2002). PMID: 12434351.

234. Kim GT, Wenz M, Park JI, Hasserodt J, Janda KD. Polyene substrates with unusual methylation patterns to probe the active sites of three catalytic antibodies. *Bioorg Med Chem* **10**(5):1249-62 (2002). PMID: 11886788.
235. Lee KJ, Mao S, Sun C, Gao C, Blixt O, Arrues S, Hom LG, Kaufmann GF, Hoffman TZ, Coyle AR, Paulson J, Felding-Habermann B, Janda KD. Phage-display selection of a human single-chain Fv antibody highly specific for melanoma and breast cancer cells using a chemoenzymatically synthesized G(M3)-carbohydrate antigen. *J Am Chem Soc* **124**(42):12439-46 (2002). PMID: 12381184.
236. Matsushita M, Janda KD. Histidine kinases as targets for new antimicrobial agents. *Bioorg Med Chem* **10**(4):855-67 (2002). PMID: 11836091.
237. Moss JA, Dickerson TJ, Janda KD. Solid phase peptide synthesis on JandaJel™ resin. *Tetrahedron Lett* **43**(1):37-40 (2002).
238. Nicholas KM, Wentworth P, Jr., Harwig CW, Wentworth AD, Shafton A, Janda KD. A cofactor approach to copper-dependent catalytic antibodies. *Proc Natl Acad Sci U S A* **99**(5):2648-53 (2002). PMID: 11880619. PMC122402.
239. Reed NN, Delgado M, Hereford K, Clapham B, Janda KD. Preparation of soluble and insoluble polymer supported IBX reagents. *Bioorg Med Chem Lett* **12**(15):2047-9 (2002). PMID: 12113839.
240. Reger TS, Janda KD. Parallel suspension polymerization for high-throughput resin synthesis. *Bioorg Med Chem Lett* **12**(6):837-40 (2002). PMID: 11958974.
241. Shimomura O, Clapham B, Spanka C, Mahajan S, Janda KD. Application of microgels as polymer supports for organic synthesis: Preparation of a small phthalide library, a scavenger, and a borohydride reagent. *J Comb Chem* **4**(5):436-41 (2002). PMID: 12217015.
242. Spanka C, Clapham B, Janda KD. Preparation of new microgel polymers and their application as supports in organic synthesis. *J Org Chem* **67**(9):3045-50 (2002). PMID: 11975565.
243. Spanka C, Wentworth P, Jr., Janda KD. Developing soluble polymers for high-throughput synthetic chemistry. *Comb Chem High Throughput Screen* **5**(3):233-40 (2002). PMID: 11966431.
244. Sun C, Wirsching P, Janda KD. Syntheses of dendritic linkers containing chlorambucil residues for the preparation of antibody-multidrug immunoconjugates. *Bioorg Med Chem Lett* **12**(16):2213-5 (2002). PMID: 12127540.
245. Wentworth P, Jr., McDunn JE, Wentworth AD, Takeuchi C, Nieva J, Jones T, Bautista C, Ruedi JM, Gutierrez A, Janda KD, Babior BM, Eschenmoser A, Lerner RA. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. *Science* **298**(5601):2195-9 (2002). PMID: 12434011.
246. Zhou B, Wirsching P, Janda KD. Human antibodies against spores of the genus *Bacillus*: A model study for detection of and protection against anthrax and the bioterrorist threat. *Proc Natl Acad Sci U S A* **99**(8):5241-6 (2002). PMID: 11959974. PMC122754.
247. Ahn JM, Wentworth P, Jr., Janda KD. Soluble polymer-supported convergent parallel library synthesis. *Chem Commun (Camb)* (4):480-1 (2003). PMID: 12638959.
248. Cannizzaro CE, Ashley JA, Janda KD, Houk KN. Experimental determination of the absolute enantioselectivity of an antibody-catalyzed Diels-Alder reaction and theoretical



- explorations of the origins of stereoselectivity. *J Am Chem Soc* **125**(9):2489-506 (2003). PMID: 12603137.
249. Chen Y, Gambs C, Abe Y, Wentworth P, Jr., Janda KD. Total synthesis of the depsipeptide FR-901375. *J Org Chem* **68**(23):8902-5 (2003). PMID: 14604360.
250. Dickerson TJ, Janda KD. Glycation of the amyloid beta-protein by a nicotine metabolite: A fortuitous chemical dynamic between smoking and Alzheimer's disease. *Proc Natl Acad Sci U S A* **100**(14):8182-7 (2003). PMID: 12815102. PMC166203.
251. Dickerson TJ, Reed NN, Janda KD. Soluble polymers as catalyst and reagent platforms: Liquid-phase methodologies. In: *Polymeric Materials in Organic Synthesis and Catalysis*. Buchmeiser MR (ed.). Weinheim, Germany: Wiley-VCH Verlag GmbH. 2003, p. 241-76.
252. Dickerson TJ, Tremblay MR, Hoffman TZ, Ruiz DI, Janda KD. Catalysis of the photo-Fries reaction: Antibody-mediated stabilization of high energy states. *J Am Chem Soc* **125**(50):15395-401 (2003). PMID: 14664584.
253. Fujimori T, Wirsching P, Janda KD. Preparation of a Kröhnke pyridine combinatorial library suitable for solution-phase biological screening. *J Comb Chem* **5**(5):625-31 (2003).
254. Gambs C, Dickerson TJ, Mahajan S, Pasternack LB, Janda KD. High-resolution diffusion-ordered spectroscopy to probe the microenvironment of JandaJel and Merrifield resins. *J Org Chem* **68**(9):3673-8 (2003). PMID: 12713377.
255. Gao C, Mao S, Ronca F, Zhuang S, Quaranta V, Wirsching P, Janda KD. De novo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods. *J Immunol Methods* **274**(1-2):185-97 (2003). PMID: 12609544.
256. Hasserodt J, Janda KD. Catalytic antibodies. In: *Encyclopedia of Catalysis*. Horvath IT (ed.). New York: Wiley. 2003, p. 440-76.
257. Lee SH, Clapham B, Koch G, Zimmermann J, Janda KD. Solid-phase rhodium carbenoid N-H insertion reactions: The synthesis of a diverse array of indoles. *J Comb Chem* **5**(2):188-96 (2003). PMID: 12625710.
258. Lee SH, Clapham B, Koch G, Zimmermann J, Janda KD. Rhodium carbenoid N-H insertion reactions of primary ureas: Solution and solid-phase synthesis of imidazolones. *Org Lett* **5**(4):511-4 (2003). PMID: 12583756.
259. Liu C, Sun C, Huang H, Janda K, Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. *Cancer Res* **63**(11):2957-64 (2003). PMID: 12782603.
260. Matsushita M, Yoshida K, Yamamoto N, Wirsching P, Lerner RA, Janda KD. High-throughput screening by using a blue-fluorescent antibody sensor. *Angew Chem Int Ed Engl* **42**(48):5984-7 (2003). PMID: 14679549.
261. Meijler MM, Matsushita M, Altobelli LJ, 3rd, Wirsching P, Janda KD. A new strategy for improved nicotine vaccines using conformationally constrained haptens. *J Am Chem Soc* **125**(24):7164-5 (2003). PMID: 12797775.
262. Moss JA, Coyle AR, Ahn JM, Meijler MM, Offer J, Janda KD. Tandem IMAC-HPLC purification of a cocaine-binding scFv antibody. *J Immunol Methods* **281**(1-2):143-8 (2003). PMID: 14580888.
263. Redwan el RM, Larsen NA, Zhou B, Wirsching P, Janda KD, Wilson IA. Expression and characterization of a humanized cocaine-binding antibody. *Biotechnol Bioeng* **82**(5):612-8 (2003). PMID: 12652485.

264. Sun C, Wirsching P, Janda KD. Enabling ScFvs as multi-drug carriers: A dendritic approach. *Bioorg Med Chem* **11**(8):1761-8 (2003). PMID: 12659762.
265. Wang Q, Raja KS, Janda KD, Lin T, Finn MG. Blue fluorescent antibodies as reporters of steric accessibility in virus conjugates. *Bioconjug Chem* **14**(1):38-43 (2003). PMID: 12526690.
266. Wentworth P, Jr., Nieva J, Takeuchi C, Galve R, Wentworth AD, Dilley RB, DeLaria GA, Saven A, Babior BM, Janda KD, Eschenmoser A, Lerner RA. Evidence for ozone formation in human atherosclerotic arteries. *Science* **302**(5647):1053-6 (2003). PMID: 14605372.
267. Wentworth P, Jr., Wentworth AD, Zhu X, Wilson IA, Janda KD, Eschenmoser A, Lerner RA. Evidence for the production of trioxxygen species during antibody-catalyzed chemical modification of antigens. *Proc Natl Acad Sci U S A* **100**(4):1490-3 (2003). PMID: 12576548. PMC149858.
268. Zhu X, Heine A, Monnat F, Houk KN, Janda KD, Wilson IA. Structural basis for antibody catalysis of a cationic cyclization reaction. *J Mol Biol* **329**(1):69-83 (2003). PMID: 12742019.
269. Zorrilla E, Fekete E, Mason BJ, Wirsching P, Janda KD, Koob GF. CRF1 antagonists for anxiety. *Eur Neuropsychopharmacol* **13**:S130-S1 (2003).
270. Ahn JM, Wentworth P, Jr., Janda KD. Probing lipase/esterase libraries for lipid A hydrolases - Discovery of biocatalysts for the detoxification of bacterially-expressed recombinant protein. *Chem Commun (Camb)* (4):364-5 (2004). PMID: 14765210.
271. Carrera MR, Ashley JA, Hoffman TZ, Isomura S, Wirsching P, Koob GF, Janda KD. Investigations using immunization to attenuate the psychoactive effects of nicotine. *Bioorg Med Chem* **12**(3):563-70 (2004). PMID: 14738965.
272. Carrera MR, Kaufmann GF, Mee JM, Meijler MM, Koob GF, Janda KD. Treating cocaine addiction with viruses. *Proc Natl Acad Sci U S A* **101**(28):10416-21 (2004). PMID: 15226496. PMC478586.
273. Carrera MR, Meijler MM, Janda KD. Cocaine pharmacology and current pharmacotherapies for its abuse. *Bioorg Med Chem* **12**(19):5019-30 (2004). PMID: 15351386.
274. Dickerson TJ, Lovell T, Meijler MM, Noodleman L, Janda KD. Nornicotine aqueous aldol reactions: Synthetic and theoretical investigations into the origins of catalysis. *J Org Chem* **69**(20):6603-9 (2004). PMID: 15387581.
275. Dickerson TJ, Reed NN, LaClair JJ, Janda KD. A precipitator for the detection of thiophilic metals in aqua. *J Am Chem Soc* **126**(50):16582-6 (2004). PMID: 15600364.
276. Dickerson TJ, Yamamoto N, Janda KD. Antibody-catalyzed oxidative degradation of nicotine using riboflavin. *Bioorg Med Chem* **12**(18):4981-7 (2004). PMID: 15336277.
277. Dickerson TJ, Yamamoto N, Ruiz DI, Janda KD. Immunological consequences of methamphetamine protein glycation. *J Am Chem Soc* **126**(37):11446-7 (2004). PMID: 15366884.
278. Felding-Habermann B, Lerner RA, Lillo A, Zhuang S, Weber MR, Arrues S, Gao C, Mao S, Saven A, Janda KD. Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. *Proc Natl Acad Sci U S A* **101**(49):17210-5 (2004). PMID: 15563590. PMC534417.

279. Janda KD, Chen D-W. Catalytic antibodies. In: Encyclopedia of Supramolecular Chemistry. 1st ed. Atwood JL, Steed JW (ed.). New York, NY: Marcel Dekker Inc. 2004, p. 193-205.
280. Kim YS, Moss JA, Janda KD. Biological tuning of synthetic tactics in solid-phase synthesis: Application to A $\beta$ (1-42). *J Org Chem* **69**(22):7776-8 (2004). PMID: 15498016.
281. Lee BS, Mahajan S, Clapham B, Janda KD. Suspension ring-opening metathesis polymerization: The preparation of norbornene-based resins for application in organic synthesis. *J Org Chem* **69**(10):3319-29 (2004). PMID: 15132537.
282. Lee S-H, Matsushita H, Clapham B, Janda KD. The direct conversion of carbamates to ureas using aluminum amides. *Tetrahedron* **60**(15):3439-43 (2004).
283. Lee SH, Matsushita H, Koch G, Zimmermann J, Clapham B, Janda KD. Smart cleavage reactions: The synthesis of an array of ureas from polymer-bound carbamates. *J Comb Chem* **6**(5):822-7 (2004). PMID: 15360219.
284. Lee SH, Yoshida K, Matsushita H, Clapham B, Koch G, Zimmermann J, Janda KD. N-H insertion reactions of primary ureas: The synthesis of highly substituted imidazolones and imidazoles from diazocarbonyls. *J Org Chem* **69**(25):8829-35 (2004). PMID: 15575764.
285. Lillo AM, Sun C, Gao C, Ditzel H, Parrish J, Gauss CM, Moss J, Felding-Habermann B, Wirsching P, Boger DL, Janda KD. A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of antitumor agents. *Chem Biol* **11**(7):897-906 (2004). PMID: 15271348.
286. Matsushita H, Lee S-H, Joung M, Clapham B, Janda KD. Smart cleavage reactions: The synthesis of benzimidazoles and benzothiazoles from polymer-bound esters. *Tetrahedron Lett* **45**(2):313-6 (2004).
287. Matsushita H, Lee SH, Yoshida K, Clapham B, Koch G, Zimmermann J, Janda KD. N-H insertion reactions of Boc-amino acid amides: Solution- and solid-phase synthesis of pyrazinones and pyrazines. *Org Lett* **6**(24):4627-9 (2004). PMID: 15548092.
288. McDunn JE, Dickerson TJ, Janda KD. Antibody catalysis of disfavored chemical reactions. In: Catalytic Antibodies. Keinan E (ed.). Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. 2004, p. 184-216.
289. Meijler MM, Hom LG, Kaufmann GF, McKenzie KM, Sun C, Moss JA, Matsushita M, Janda KD. Synthesis and biological validation of a ubiquitous quorum-sensing molecule. *Angew Chem Int Ed Engl* **43**(16):2106-8 (2004). PMID: 15083457.
290. Meijler MM, Matsushita M, Wirsching P, Janda KD. Development of immunopharmacotherapy against drugs of abuse. *Curr Drug Discov Technol* **1**(1):77-89 (2004). PMID: 16472221.
291. Qi L, Meijler MM, Lee SH, Sun C, Janda KD. Solid-phase synthesis of anandamide analogues. *Org Lett* **6**(10):1673-5 (2004). PMID: 15128264.
292. Xu Y, Yamamoto N, Janda KD. Catalytic antibodies: Hapten design strategies and screening methods. *Bioorg Med Chem* **12**(20):5247-68 (2004). PMID: 15388154.
293. Brogan AP, Dickerson TJ, Boldt GE, Janda KD. Altered retinoid homeostasis catalyzed by a nicotine metabolite: Implications in macular degeneration and normal development. *Proc Natl Acad Sci U S A* **102**(30):10433-8 (2005). PMID: 16014706. PMC1180800.

294. Carrera MR, Trigo JM, Wirsching P, Roberts AJ, Janda KD. Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. *Pharmacol Biochem Behav* **81**(4):709-14 (2005). PMID: 16005948.
295. Dickerson TJ, Beuscher AEt, Rogers CJ, Hixon MS, Yamamoto N, Xu Y, Olson AJ, Janda KD. Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library. *Biochemistry* **44**(45):14845-53 (2005). PMID: 16274232.
296. Dickerson TJ, Janda KD. Recent advances for the treatment of cocaine abuse: Central nervous system immunopharmacotherapy. *AAPS J* **7**(3):E579-86 (2005). PMID: 16353936. PMC2751261.
297. Eubanks LM, Dickerson TJ, Janda KD. Vitamin B2-mediated cellular photoinhibition of botulinum neurotoxin A. *FEBS Lett* **579**(24):5361-4 (2005). PMID: 16198354.
298. Kaufmann GF, Meijler MM, Sun C, Chen DW, Kujawa DP, Mee JM, Hoffman TZ, Wirsching P, Lerner RA, Janda KD. Enzymatic incorporation of an antibody-activated blue fluorophore into DNA. *Angew Chem Int Ed Engl* **44**(14):2144-8 (2005). PMID: 15742317.
299. Kaufmann GF, Sartorio R, Lee SH, Rogers CJ, Meijler MM, Moss JA, Clapham B, Brogan AP, Dickerson TJ, Janda KD. Revisiting quorum sensing: Discovery of additional chemical and biological functions for 3-oxo-N-acylhomoserine lactones. *Proc Natl Acad Sci U S A* **102**(2):309-14 (2005). PMID: 15623555. PMC544315.
300. Kim Y, Lillo A, Moss JA, Janda KD. A contiguous stretch of methionine residues mediates the energy-dependent internalization mechanism of a cell-penetrating peptide. *Mol Pharm* **2**(6):528-35 (2005). PMID: 16323960.
301. Lee BS, Mahajan S, Janda KD. Cross-linked poly(4-vinylpyridine/styrene) copolymers as a support for immobilization of ytterbium triflate. *Tetrahedron* **61**(12):3081-6 (2005).
302. Lee BS, Mahajan S, Janda KD. Molecular iodine-catalyzed imine activation for three-component nucleophilic addition reactions. *Synlett* **2005**(08):1325-7 (2005).
303. Lee BS, Mahajan S, Janda KD. Novel method for catalyst immobilization using an ionic polymer: A case study using recyclable ytterbium triflate. *Tetrahedron Lett* **46**(5):807-10 (2005).
304. Lee BS, Mahajan S, Janda KD. Asymmetric dihydroxylation catalyzed by ionic polymer-supported osmium tetroxide. *Tetrahedron Lett* **46**(26):4491-3 (2005).
305. Lowery CA, McKenzie KM, Qi L, Meijler MM, Janda KD. Quorum sensing in *Vibrio harveyi*: Probing the specificity of the LuxP binding site. *Bioorg Med Chem Lett* **15**(9):2395-8 (2005). PMID: 15837332.
306. Matsushita H, Yamamoto N, Meijler MM, Wirsching P, Lerner RA, Matsushita M, Janda KD. Chiral sensing using a blue fluorescent antibody. *Mol Biosyst* **1**(4):303-6 (2005). PMID: 16880995.
307. Matsushita M, Meijler MM, Wirsching P, Lerner RA, Janda KD. A blue fluorescent antibody-cofactor sensor for mercury. *Org Lett* **7**(22):4943-6 (2005). PMID: 16235928.
308. McKenzie KM, Meijler MM, Lowery CA, Boldt GE, Janda KD. A furanosyl-carbonate autoinducer in cell-to-cell communication of *V. harveyi*. *Chem Commun (Camb)* (38):4863-5 (2005). PMID: 16193140.
309. Meijler MM, Kaufmann GF, Qi L, Mee JM, Coyle AR, Moss JA, Wirsching P, Matsushita M, Janda KD. Fluorescent cocaine probes: A tool for the selection and engineering of therapeutic antibodies. *J Am Chem Soc* **127**(8):2477-84 (2005). PMID: 15725002.

310. Moss JA, Lillo A, Kim YS, Gao C, Ditzel H, Janda KD. A dimerization "switch" in the internalization mechanism of a cell-penetrating peptide. *J Am Chem Soc* **127**(2):538-9 (2005). PMID: 15643874.
311. Qi L, Yamamoto N, Meijler MM, Altobelli LJ, 3rd, Koob GF, Wirsching P, Janda KD.  $\Delta^9$ -tetrahydrocannabinol immunochemical studies: Haptens, monoclonal antibodies, and a convenient synthesis of radiolabeled  $\Delta^9$ -tetrahydrocannabinol. *J Med Chem* **48**(23):7389-99 (2005). PMID: 16279798.
312. Reed NN, Dickerson TJ, Boldt GE, Janda KD. Enantio-reversal in the Sharpless asymmetric epoxidation reaction controlled by the molecular weight of a covalently appended achiral polymer. *J Org Chem* **70**(5):1728-31 (2005). PMID: 15730294.
313. Rogers CJ, Dickerson TJ, Brogan AP, Janda KD. Hammett correlation of nor-nicotine analogues in the aqueous aldol reaction: Implications for green organocatalysis. *J Org Chem* **70**(9):3705-8 (2005). PMID: 15845010.
314. Rogers CJ, Dickerson TJ, Wentworth P, Janda KD. A high-swelling reagent scaffold suitable for use in aqueous and organic solvents. *Tetrahedron* **61**(51):12140-4 (2005).
315. Rogers CJ, Mee JM, Kaufmann GF, Dickerson TJ, Janda KD. Toward cocaine esterase therapeutics. *J Am Chem Soc* **127**(28):10016-7 (2005). PMID: 16011362. PMC1352337.
316. Shimomura O, Se Lee B, Meth S, Suzuki H, Mahajan S, Nomura R, Janda KD. Synthesis and application of polytetrahydrofuran-grafted polystyrene (PS-PTHF) resin supports for organic synthesis. *Tetrahedron* **61**(51):12160-7 (2005).
317. Shute TS, Matsushita M, Dickerson TJ, La Clair JJ, Janda KD, Burkart MD. A site-specific bifunctional protein labeling system for affinity and fluorescent analysis. *Bioconjug Chem* **16**(6):1352-5 (2005). PMID: 16287229.
318. Toker JD, Tremblay MR, Yli-Kauhaluoma J, Wentworth AD, Zhou B, Wentworth P, Jr., Janda KD. Exploring the scope of the 29G12 antibody catalyzed 1,3-dipolar cycloaddition reaction. *J Org Chem* **70**(20):7810-5 (2005). PMID: 16277300.
319. Xu Y, Yamamoto N, Ruiz DI, Kubitz DS, Janda KD. Squaric monoamide monoester as a new class of reactive immunization hapten for catalytic antibodies. *Bioorg Med Chem Lett* **15**(19):4304-7 (2005). PMID: 16046128.
320. Yamashita M, Lee S-H, Koch G, Zimmermann J, Clapham B, Janda KD. Solid-phase synthesis of oxazolones and other heterocycles via Wang resin-bound diazocarbonyls. *Tetrahedron Lett* **46**(33):5495-8 (2005).
321. Boldt GE, Dickerson TJ, Janda KD. Emerging chemical and biological approaches for the preparation of discovery libraries. *Drug Discov Today* **11**(3-4):143-8 (2006). PMID: 16533712.
322. Boldt GE, Eubanks LM, Janda KD. Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. *Chem Commun (Camb)* (29):3063-5 (2006). PMID: 16855686.
323. Boldt GE, Kennedy JP, Hixon MS, McAllister LA, Barbieri JT, Tzipori S, Janda KD. Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin A inhibitors. *J Comb Chem* **8**(4):513-21 (2006). PMID: 16827563. PMC2644723.

324. Boldt GE, Kennedy JP, Janda KD. Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. *Org Lett* **8**(8):1729-32 (2006). PMID: 16597152. PMC2733786.
325. Brogan AP, Dickerson TJ, Janda KD. Enamine-based aldol organocatalysis in water: Are they really "all wet"? *Angew Chem Int Ed Engl* **45**(48):8100-2 (2006). PMID: 17001595.
326. Dickerson TJ, Janda KD. The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. *ACS Chem Biol* **1**(6):359-69 (2006). PMID: 17163773.
327. Eubanks LM, Rogers CJ, Beuscher AEt, Koob GF, Olson AJ, Dickerson TJ, Janda KD. A molecular link between the active component of marijuana and Alzheimer's disease pathology. *Mol Pharm* **3**(6):773-7 (2006). PMID: 17140265. PMC2562334.
328. Fu Z, Chen S, Baldwin MR, Boldt GE, Crawford A, Janda KD, Barbieri JT, Kim JJ. Light chain of botulinum neurotoxin serotype A: Structural resolution of a catalytic intermediate. *Biochemistry* **45**(29):8903-11 (2006). PMID: 16846233.
329. Kaufmann GF, Sartorio R, Lee SH, Mee JM, Altobelli LJ, 3rd, Kujawa DP, Jeffries E, Clapham B, Meijler MM, Janda KD. Antibody interference with N-acyl homoserine lactone-mediated bacterial quorum sensing. *J Am Chem Soc* **128**(9):2802-3 (2006). PMID: 16506750. PMC2546487.
330. Kim Y, Lillo AM, Steiniger SC, Liu Y, Ballatore C, Anichini A, Mortarini R, Kaufmann GF, Zhou B, Felding-Habermann B, Janda KD. Targeting heat shock proteins on cancer cells: Selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. *Biochemistry* **45**(31):9434-44 (2006). PMID: 16878978.
331. Kravchenko VV, Kaufmann GF, Mathison JC, Scott DA, Katz AZ, Wood MR, Brogan AP, Lehmann M, Mee JM, Iwata K, Pan Q, Fearn C, Knaus UG, Meijler MM, Janda KD, Ulevitch RJ. N-(3-oxo-acyl)homoserine lactones signal cell activation through a mechanism distinct from the canonical pathogen-associated molecular pattern recognition receptor pathways. *J Biol Chem* **281**(39):28822-30 (2006). PMID: 16893899.
332. Lillo AM, McKenzie KM, Janda KD. Phage-displayed antibody libraries. In: *Cell Biology: A Laboratory Handbook*. Celis JE (ed.). Elsevier Academic, USA. 2006, p. 491-6.
333. Ma H, Zhou B, Kim Y, Janda KD. A cyclic peptide-polymer probe for the detection of *Clostridium botulinum* neurotoxin serotype A. *Toxicon* **47**(8):901-8 (2006). PMID: 16730044.
334. McAllister LA, Hixon MS, Kennedy JP, Dickerson TJ, Janda KD. Superactivation of the botulinum neurotoxin serotype A light chain metalloprotease: A new wrinkle in botulinum neurotoxin. *J Am Chem Soc* **128**(13):4176-7 (2006). PMID: 16568962. PMC2529174.
335. Moss JA, Stokols S, Hixon MS, Ashley FT, Chang JY, Janda KD. Solid-phase synthesis and kinetic characterization of fluorogenic enzyme-degradable hydrogel cross-linkers. *Biomacromolecules* **7**(4):1011-6 (2006). PMID: 16602715. PMC2546486.
336. Rogers CJ, Dickerson TJ, Janda KD. Kinetic isotope and thermodynamic analysis of the nornicotine-catalyzed aqueous aldol reaction. *Tetrahedron* **62**(2):352-6 (2006).
337. Rogers CJ, Eubanks LM, Dickerson TJ, Janda KD. Unexpected acetylcholinesterase activity of cocaine esterases. *J Am Chem Soc* **128**(48):15364-5 (2006). PMID: 17131989. PMC2533137.

338. Shigenaga A, Moss JA, Ashley FT, Kaufmann GF, Janda KD. Solid-phase synthesis and cyclative cleavage of quorum sensing -depsipeptide analogues by acylphenyldiazene activation. *Synlett* **2006**(4):0551-4 (2006).
339. Wu W, Luo Y, Sun C, Liu Y, Kuo P, Varga J, Xiang R, Reisfeld R, Janda KD, Edgington TS, Liu C. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. *Cancer Res* **66**(2):970-80 (2006). PMID: 16424032.
340. Xu Y, Lu H, Kennedy JP, Yan X, McAllister LA, Yamamoto N, Moss JA, Boldt GE, Jiang S, Janda KD. Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. *J Comb Chem* **8**(4):531-9 (2006). PMID: 16827565. PMC2529179.
341. Xu Y, Shi J, Yamamoto N, Moss JA, Vogt PK, Janda KD. A credit-card library approach for disrupting protein-protein interactions. *Bioorg Med Chem* **14**(8):2660-73 (2006). PMID: 16384710.
342. Zhang L, Long H, Boldt GE, Janda KD, Schatz GC, Lewis FD.  $\alpha$ - and  $\beta$ -stilbenosides as base-pair surrogates in DNA hairpins. *Org Biomol Chem* **4**(2):314-22 (2006). PMID: 16391774.
343. Zhu X, Dickerson TJ, Rogers CJ, Kaufmann GF, Mee JM, McKenzie KM, Janda KD, Wilson IA. Complete reaction cycle of a cocaine catalytic antibody at atomic resolution. *Structure* **14**(2):205-16 (2006). PMID: 16472740.
344. Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, Meijler MM, Janda KD. Vaccination against weight gain. *Proc Natl Acad Sci U S A* **103**(35):13226-31 (2006). PMID: 16891413. PMC1559781.
345. Brogan AP, Dickerson TJ, Janda KD. Nornicotine-organocatalyzed aqueous reduction of  $\alpha,\beta$ -unsaturated aldehydes. *Chem Commun (Camb)* (46):4952-4 (2007). PMID: 18361380.
346. Brogan AP, Eubanks LM, Koob GF, Dickerson TJ, Janda KD. Antibody-catalyzed oxidation of  $\Delta$ (9)-tetrahydrocannabinol. *J Am Chem Soc* **129**(12):3698-702 (2007). PMID: 17335216.
347. Capkova K, Yoneda Y, Dickerson TJ, Janda KD. Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors. *Bioorg Med Chem Lett* **17**(23):6463-6 (2007). PMID: 17951059. PMC2170532.
348. De Lamo Marin S, Xu Y, Meijler MM, Janda KD. Antibody catalyzed hydrolysis of a quorum sensing signal found in Gram-negative bacteria. *Bioorg Med Chem Lett* **17**(6):1549-52 (2007). PMID: 17254784.
349. Debler EW, Kaufmann GF, Kirchdoerfer RN, Mee JM, Janda KD, Wilson IA. Crystal structures of a quorum-quenching antibody. *J Mol Biol* **368**(5):1392-402 (2007). PMID: 17400249. PMC1994716.
350. Dickerson TJ, McKenzie KM, Hoyt AS, Wood MR, Janda KD, Brenner SB, Lerner RA. Phage escape libraries for checkmate analysis. *Proc Natl Acad Sci U S A* **104**(31):12703-8 (2007). PMID: 17646645. PMC1937530.
351. Eubanks LM, Dickerson TJ, Janda KD. Technological advancements for the detection of and protection against biological and chemical warfare agents. *Chem Soc Rev* **36**(3):458-70 (2007). PMID: 17325785.
352. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, Tepp WH, Baldwin MR, Malizio CJ, Goodnough MC, Barbieri JT, Johnson EA, Boger DL, Dickerson TJ, Janda KD. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum

- neurotoxin A antagonists. *Proc Natl Acad Sci U S A* **104**(8):2602-7 (2007). PMID: 17293454. PMC1815229.
353. Ino A, Dickerson TJ, Janda KD. Positional linker effects in haptens for cocaine immunopharmacotherapy. *Bioorg Med Chem Lett* **17**(15):4280-3 (2007). PMID: 17531484.
354. Liu Y, Steiniger SC, Kim Y, Kaufmann GF, Felding-Habermann B, Janda KD. Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. *Mol Pharm* **4**(3):435-47 (2007). PMID: 17373820. PMC2533281.
355. McAllister LA, Hixon MS, Schwartz R, Kubitz DS, Janda KD. Synthesis and application of a novel ligand for affinity chromatography based removal of endotoxin from antibodies. *Bioconjug Chem* **18**(2):559-66 (2007). PMID: 17315943.
356. McKenzie KM, Mee JM, Rogers CJ, Hixon MS, Kaufmann GF, Janda KD. Identification and characterization of single chain anti-cocaine catalytic antibodies. *J Mol Biol* **365**(3):722-31 (2007). PMID: 17084858. PMC1828637.
357. Park J, Jagasia R, Kaufmann GF, Mathison JC, Ruiz DI, Moss JA, Meijler MM, Ulevitch RJ, Janda KD. Infection control by antibody disruption of bacterial quorum sensing signaling. *Chem Biol* **14**(10):1119-27 (2007). PMID: 17961824. PMC2088803.
358. Silvaggi NR, Boldt GE, Hixon MS, Kennedy JP, Tzipori S, Janda KD, Allen KN. Structures of *Clostridium botulinum* neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility. *Chem Biol* **14**(5):533-42 (2007). PMID: 17524984.
359. Steiniger SC, Altobelli LJ, 3rd, Zhou B, Janda KD. Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen. *Mol Immunol* **44**(10):2749-55 (2007). PMID: 17210180.
360. Treweek J, Wee S, Koob GF, Dickerson TJ, Janda KD. Self-vaccination by methamphetamine glycation products chemically links chronic drug abuse and cardiovascular disease. *Proc Natl Acad Sci U S A* **104**(28):11580-4 (2007). PMID: 17592122. PMC1913859.
361. Xu Y, Hixon MS, Dawson PE, Janda KD. Development of a FRET assay for monitoring of HIV gp41 core disruption. *J Org Chem* **72**(18):6700-7 (2007). PMID: 17685571.
362. Xu Y, Hixon MS, Yamamoto N, McAllister LA, Wentworth AD, Wentworth P, Jr., Janda KD. Antibody-catalyzed anaerobic destruction of methamphetamine. *Proc Natl Acad Sci U S A* **104**(10):3681-6 (2007). PMID: 17360412. PMC1820643.
363. Zhou H, Zhou B, Ma H, Carney C, Janda KD. Selection and characterization of human monoclonal antibodies against Abrin by phage display. *Bioorg Med Chem Lett* **17**(20):5690-2 (2007). PMID: 17764932.
364. Capkova K, Hixon MS, McAllister LA, Janda KD. Toward the discovery of potent inhibitors of botulinum neurotoxin A: Development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. *Chem Commun (Camb)* (30):3525-7 (2008). PMID: 18654701.
365. Debler EW, Kaufmann GF, Meijler MM, Heine A, Mee JM, Pljevaljcic G, Di Bilio AJ, Schultz PG, Millar DP, Janda KD, Wilson IA, Gray HB, Lerner RA. Deeply inverted electron-hole recombination in a luminescent antibody-stilbene complex. *Science* **319**(5867):1232-5 (2008). PMID: 18309081.
366. Janda KD. Instant insight: Communicating with nature. *Chemical Biology* **3**:B47 (2008).



367. Kaufmann GF, Park J, Janda KD. Bacterial quorum sensing: A new target for anti-infective immunotherapy. *Expert Opin Biol Ther* **8**(6):719-24 (2008). PMID: 18476783.
368. Kaufmann GF, Park J, Mee JM, Ulevitch RJ, Janda KD. The quorum quenching antibody RS2-1G9 protects macrophages from the cytotoxic effects of the *Pseudomonas aeruginosa* quorum sensing signalling molecule N-3-oxo-dodecanoyl-homoserine lactone. *Mol Immunol* **45**(9):2710-4 (2008). PMID: 18304641. PMC2359578.
369. Kravchenko VV, Kaufmann GF, Mathison JC, Scott DA, Katz AZ, Grauer DC, Lehmann M, Meijler MM, Janda KD, Ulevitch RJ. Modulation of gene expression via disruption of NF- $\kappa$ B signaling by a bacterial small molecule. *Science* **321**(5886):259-63 (2008). PMID: 18566250.
370. Lowery CA, Dickerson TJ, Janda KD. Interspecies and interkingdom communication mediated by bacterial quorum sensing. *Chem Soc Rev* **37**(7):1337-46 (2008). PMID: 18568160.
371. Lowery CA, Park J, Kaufmann GF, Janda KD. An unexpected switch in the modulation of AI-2-based quorum sensing discovered through synthetic 4,5-dihydroxy-2,3-pentanedione analogues. *J Am Chem Soc* **130**(29):9200-1 (2008). PMID: 18576653. PMC2668569.
372. Mayorov AV, Amara N, Chang JY, Moss JA, Hixon MS, Ruiz DI, Meijler MM, Zorrilla EP, Janda KD. Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice. *Proc Natl Acad Sci U S A* **105**(45):17487-92 (2008). PMID: 18981425. PMC2582297.
373. Park J, Dickerson TJ, Janda KD. Major sperm protein as a diagnostic antigen for onchocerciasis. *Bioorg Med Chem* **16**(15):7206-9 (2008). PMID: 18632276.
374. Park J, Kaufmann GF, Bowen JP, Arbiser JL, Janda KD. Solenopsin A, a venom alkaloid from the fire ant *Solenopsis invicta*, inhibits quorum-sensing signaling in *Pseudomonas aeruginosa*. *J Infect Dis* **198**(8):1198-201 (2008). PMID: 18713055.
375. Richardson HN, Zhao Y, Fekete EM, Funk CK, Wirsching P, Janda KD, Zorrilla EP, Koob GF. MPZP: A novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. *Pharmacol Biochem Behav* **88**(4):497-510 (2008). PMID: 18031798. PMC3319109.
376. Steiniger SC, Coppinger JA, Kruger JA, Yates J, 3rd, Janda KD. Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. *Stem Cells* **26**(12):3037-46 (2008). PMID: 18802034. PMC2745975.
377. Treweek JB, Sun C, Mayorov AV, Qi L, Levy CL, Roberts AJ, Dickerson TJ, Janda KD. Prevention of drug-induced memory impairment by immunopharmacotherapy. *J Med Chem* **51**(21):6866-75 (2008). PMID: 18921991. PMC2661766.
378. Willis B, Eubanks LM, Dickerson TJ, Janda KD. The strange case of the botulinum neurotoxin: Using chemistry and biology to modulate the most deadly poison. *Angew Chem Int Ed Engl* **47**(44):8360-79 (2008). PMID: 18844202.
379. Willis B, Eubanks LM, Wood MR, Janda KD, Dickerson TJ, Lerner RA. Biologically templated organic polymers with nanoscale order. *Proc Natl Acad Sci U S A* **105**(5):1416-9 (2008). PMID: 18216240. PMC2234158.

380. Yoneda Y, Steiniger SC, Capkova K, Mee JM, Liu Y, Kaufmann GF, Janda KD. A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy. *Bioorg Med Chem Lett* **18**(5):1632-6 (2008). PMID: 18243696. PMC2288489.
381. Zarebski LM, Vaughan K, Sidney J, Peters B, Grey H, Janda KD, Casadevall A, Sette A. Analysis of epitope information related to *Bacillus anthracis* and *Clostridium botulinum*. *Expert Rev Vaccines* **7**(1):55-74 (2008). PMID: 18251694. PMC3319117.
382. Zhou B, Carney C, Janda KD. Selection and characterization of human antibodies neutralizing *Bacillus anthracis* toxin. *Bioorg Med Chem* **16**(4):1903-13 (2008). PMID: 18023190. PMC2268906.
383. Zhou B, Pellett S, Tepp WH, Zhou H, Johnson EA, Janda KD. Delineating the susceptibility of botulinum neurotoxins to denaturation through thermal effects. *FEBS Lett* **582**(10):1526-31 (2008). PMID: 18396167.
384. Brogan AP, Dickerson TJ, Janda KD. Catalytic antibodies: Past, Present, and Future. In: Wiley Encyclopedia of Chemical Biology. Begley TP (ed.). John Wiley & Sons. 2009, p. 1987-2003.
385. Capkova K, Salzameda NT, Janda KD. Investigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins. *Toxicon* **54**(5):575-82 (2009). PMID: 19327377. PMC2730986.
386. Fischer A, Nakai Y, Eubanks LM, Clancy CM, Tepp WH, Pellett S, Dickerson TJ, Johnson EA, Janda KD, Montal M. Bimodal modulation of the botulinum neurotoxin protein-conducting channel. *Proc Natl Acad Sci U S A* **106**(5):1330-5 (2009). PMID: 19164566. PMC2635780.
387. Frederick MO, De Lamo Marin S, Janda KD, Nicolaou KC, Dickerson TJ. Monoclonal antibodies with orthogonal azaspiracid epitopes. *ChemBioChem* **10**(10):1625-9 (2009). PMID: 19492388. PMC2750835.
388. Lowery CA, Abe T, Park J, Eubanks LM, Sawada D, Kaufmann GF, Janda KD. Revisiting AI-2 quorum sensing inhibitors: Direct comparison of alkyl-DPD analogues and a natural product fimbrolide. *J Am Chem Soc* **131**(43):15584-5 (2009). PMID: 19824634. PMC2784249.
389. Lowery CA, Park J, Gloeckner C, Meijler MM, Mueller RS, Boshoff HI, Ulrich RL, Barry CE, 3rd, Bartlett DH, Kravchenko VV, Kaufmann GF, Janda KD. Defining the mode of action of tetramic acid antibacterials derived from *Pseudomonas aeruginosa* quorum sensing signals. *J Am Chem Soc* **131**(40):14473-9 (2009). PMID: 19807189. PMC2760024.
390. Moreno AY, Janda KD. Immunopharmacotherapy: Vaccination strategies as a treatment for drug abuse and dependence. *Pharmacol Biochem Behav* **92**(2):199-205 (2009). PMID: 19350728. PMC2768391.
391. Nakai Y, Tepp WH, Dickerson TJ, Johnson EA, Janda KD. Function-oriented synthesis applied to the anti-botulinum natural product toosendanin. *Bioorg Med Chem* **17**(3):1152-7 (2009). PMID: 19131252. PMC2661763.
392. Pires-Alves M, Ho M, Aberle KK, Janda KD, Wilson BA. Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. *Toxicon* **53**(4):392-9 (2009). PMID: 19168088. PMC2649687.

393. Salzameda NT, Barbieri JT, Janda KD. Synthetic substrate for application in both high and low throughput assays for botulinum neurotoxin B protease inhibitors. *Bioorg Med Chem Lett* **19**(20):5848-50 (2009). PMID: 19747823. PMC2753755.
394. Sheng J, Oyler G, Zhou B, Janda K, Shoemaker CB. Identification and characterization of a novel cell-penetrating peptide. *Biochem Biophys Res Commun* **382**(2):236-40 (2009). PMID: 19084505. PMC3006162.
395. Steiniger S, Janda KD. The good, the bad, and the very bad: A new platform strategy to identify drug targets in cancer stem cells. *BIOforum Europe* **6**:25 (2009).
396. Treweek JB, Dickerson TJ, Janda KD. Drugs of abuse that mediate advanced glycation end product formation: A chemical link to disease pathology. *Acc Chem Res* **42**(5):659-69 (2009). PMID: 19275211. PMC2982794.
397. Treweek JB, Moreno AY, Janda KD. SLEEPLESS-ness and insomnia in fruit flies. *Angew Chem Int Ed Engl* **48**(3):438-40 (2009). PMID: 19072956.
398. Zhou H, Zhou B, Pellett S, Johnson EA, Janda KD. Selection and characterization of a human monoclonal neutralizing antibody for *Clostridium botulinum* neurotoxin serotype B. *Bioorg Med Chem Lett* **19**(3):662-4 (2009). PMID: 19112017. PMC2645068.
399. Capkova K, Hixon MS, Pellett S, Barbieri JT, Johnson EA, Janda KD. Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase. *Bioorg Med Chem Lett* **20**(1):206-8 (2010). PMID: 19914829. PMC2818383.
400. Denery JR, Nunes AA, Hixon MS, Dickerson TJ, Janda KD. Metabolomics-based discovery of diagnostic biomarkers for onchocerciasis. *PLoS Negl Trop Dis* **4**(10):e834 (2010). PMID: 20957145. PMC2950146.
401. Eubanks LM, Silhar P, Salzameda NT, Zakhari JS, Xiaochuan F, Barbieri JT, Shoemaker CB, Hixon MS, Janda KD. Identification of a natural product antagonist against the botulinum neurotoxin light chain protease. *ACS Med Chem Lett* **1**(6):268-72 (2010). PMID: 20959871. PMC2955888.
402. Fukuchi K, Steiniger SC, Deryugina E, Liu Y, Lowery CA, Gloeckner C, Zhou B, Kaufmann GF, Quigley JP, Janda KD. Inhibition of tumor metastasis: Functional immune modulation of the CUB domain containing protein 1. *Mol Pharm* **7**(1):245-53 (2010). PMID: 19916495. PMC2815031.
403. Garner AL, Janda KD. cat-ELCCA: A robust method to monitor the fatty acid acyltransferase activity of ghrelin O-acyltransferase (GOAT). *Angew Chem Int Ed Engl* **49**(50):9630-4 (2010). PMID: 20845345. PMC3485397.
404. Gloeckner C, Garner AL, Mersha F, Oksov Y, Tricoche N, Eubanks LM, Lustigman S, Kaufmann GF, Janda KD. Repositioning of an existing drug for the neglected tropical disease onchocerciasis. *Proc Natl Acad Sci U S A* **107**(8):3424-9 (2010). PMID: 20142509. PMC2840490.
405. Lowery CA, Salzameda NT, Sawada D, Kaufmann GF, Janda KD. Medicinal chemistry as a conduit for the modulation of quorum sensing. *J Med Chem* **53**(21):7467-89 (2010). PMID: 20669927. PMC2974035.
406. Mayorov AV, Willis B, Di Mola A, Adler D, Borgia J, Jackson O, Wang J, Luo Y, Tang L, Knapp RJ, Natarajan C, Goodnough MC, Zilberberg N, Simpson LL, Janda KD. Symptomatic

- relief of botulinum neurotoxin/A intoxication with aminopyridines: A new twist on an old molecule. *ACS Chem Biol* **5**(12):1183-91 (2010). PMID: 20936877. PMC3003761.
407. Moreno AY, Azar MR, Warren NA, Dickerson TJ, Koob GF, Janda KD. A critical evaluation of a nicotine vaccine within a self-administration behavioral model. *Mol Pharm* **7**(2):431-41 (2010). PMID: 20104903.
408. Nakai Y, Pellett S, Tepp WH, Johnson EA, Janda KD. Toosendanin: Synthesis of the AB-ring and investigations of its anti-botulinum properties (Part II). *Bioorg Med Chem* **18**(3):1280-7 (2010). PMID: 20044261. PMC2819598.
409. Silhar P, Capkova K, Salzameda NT, Barbieri JT, Hixon MS, Janda KD. Botulinum neurotoxin A protease: Discovery of natural product exosite inhibitors. *J Am Chem Soc* **132**(9):2868-9 (2010). PMID: 20158239. PMC2832098.
410. Staflin K, Krueger JS, Hachmann J, Forsyth JS, Lorgner M, Steiniger SC, Mee J, Pop C, Salvesen GS, Janda KD, Felding-Habermann B. Targeting activated integrin  $\alpha\beta 3$  with patient-derived antibodies impacts late-stage multiorgan metastasis. *Clin Exp Metastasis* **27**(4):217-31 (2010). PMID: 20225083. PMC4830478.
411. Stowe GN, Silhar P, Hixon MS, Silvaggi NR, Allen KN, Moe ST, Jacobson AR, Barbieri JT, Janda KD. Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease. *Org Lett* **12**(4):756-9 (2010). PMID: 20092262. PMC2821465.
412. Thyagarajan B, Potian JG, Garcia CC, Hognason K, Capkova K, Moe ST, Jacobson AR, Janda KD, McArdle JJ. Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions. *Neuropharmacology* **58**(8):1189-98 (2010). PMID: 20211192. PMC2867082.
413. Treweek JB, Roberts AJ, Janda KD. Superadditive effects of ethanol and flunitrazepam: Implications of using immunopharmacotherapy as a therapeutic. *Mol Pharm* **7**(6):2056-68 (2010). PMID: 20849117. PMC2997924.
414. Eubanks LM, Stowe GN, De Lamo Marin S, Mayorov AV, Hixon MS, Janda KD. Identification of  $\alpha 2$  macroglobulin as a major serum ghrelin esterase. *Angew Chem Int Ed Engl* **50**(45):10699-702 (2011). PMID: 21928452. PMC3515674.
415. Garner AL, Gloeckner C, Tricoche N, Zakhari JS, Samje M, Cho-Ngwa F, Lustigman S, Janda KD. Design, synthesis, and biological activities of closantel analogues: Structural promiscuity and its impact on *Onchocerca volvulus*. *J Med Chem* **54**(11):3963-72 (2011). PMID: 21534605.
416. Garner AL, Janda KD. Shedding light on the ghrelin/GOAT metabolism saga. *ChemBioChem* **12**(4):523-5 (2011). PMID: 21254317.
417. Garner AL, Janda KD. Protein-protein interactions and cancer: Targeting the central dogma. *Curr Top Med Chem* **11**(3):258-80 (2011). PMID: 21320057.
418. Garner AL, Janda KD. A small molecule antagonist of ghrelin O-acyltransferase (GOAT). *Chem Commun (Camb)* **47**(26):7512-4 (2011). PMID: 21594284.
419. Garner AL, Park J, Zakhari JS, Lowery CA, Struss AK, Sawada D, Kaufmann GF, Janda KD. A multivalent probe for AI-2 quorum-sensing receptors. *J Am Chem Soc* **133**(40):15934-7 (2011). PMID: 21913711. PMC3203215.
420. Garner AL, Yu J, Struss AK, Lowery CA, Zhu J, Kim SK, Park J, Mayorov AV, Kaufmann GF, Kravchenko VV, Janda KD. Synthesis of 'clickable' acylhomoserine lactone quorum

- sensing probes: Unanticipated effects on mammalian cell activation. *Bioorg Med Chem Lett* **21**(9):2702-5 (2011). PMID: 21190852. PMC3081916.
421. Hicks MJ, De BP, Rosenberg JB, Davidson JT, Moreno AY, Janda KD, Wee S, Koob GF, Hackett NR, Kaminsky SM, Worgall S, Toth M, Mezey JG, Crystal RG. Cocaine analog coupled to disrupted adenovirus: A vaccine strategy to evoke high-titer immunity against addictive drugs. *Mol Ther* **19**(3):612-9 (2011). PMID: 21206484. PMC3048190.
422. Hoon S, Zhou B, Janda KD, Brenner S, Scolnick J. Aptamer selection by high-throughput sequencing and informatic analysis. *Biotechniques* **51**(6):413-6 (2011). PMID: 22150332.
423. Janda KD. Editor's Note. *Bioorg Med Chem* **19**(1):20 (2011).
424. Janda KD, Treweek JB. Vaccines targeting drugs of abuse: Is the glass half-empty or half-full? *Nat Rev Immunol* **12**(1):67-72 (2011). PMID: 22173478.
425. Kaufmann GF, Park J, Mayorov AV, Kubitz DM, Janda KD. Generation of quorum quenching antibodies. *Methods Mol Biol* **692**:299-311 (2011). PMID: 21031321.
426. Kirchdoerfer RN, Garner AL, Flack CE, Mee JM, Horswill AR, Janda KD, Kaufmann GF, Wilson IA. Structural basis for ligand recognition and discrimination of a quorum-quenching antibody. *J Biol Chem* **286**(19):17351-8 (2011). PMID: 21454495. PMC3089576.
427. Koob G, Hicks MJ, Wee S, Rosenberg JB, De BP, Kaminsky SM, Moreno A, Janda KD, Crystal RG. Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus. *CNS Neurol Disord Drug Targets* **10**(8):899-904 (2011). PMID: 22229312. PMC3369545.
428. Li Z, Garner AL, Gloeckner C, Janda KD, Carlow CK. Targeting the *Wolbachia* cell division protein FtsZ as a new approach for antifilarial therapy. *PLoS Negl Trop Dis* **5**(11):e1411 (2011). PMID: 22140592. PMC3226453.
429. Liu Y, Jiang P, Capkova K, Xue D, Ye L, Sinha SC, Mackman N, Janda KD, Liu C. Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. *Cancer Res* **71**(20):6492-502 (2011). PMID: 21880589.
430. Lowery CA, Kaufmann GF, Janda KD. Determination of acyl homoserine lactone and tetramic acid concentrations in biological samples. *Methods Mol Biol* **692**:101-11 (2011). PMID: 21031307.
431. Moreno AY, Janda KD. Current challenges for the creation of effective vaccines against drugs of abuse. *Expert Rev Vaccines* **10**(12):1637-9 (2011). PMID: 22085165.
432. Moreno AY, Mayorov AV, Janda KD. Impact of distinct chemical structures for the development of a methamphetamine vaccine. *J Am Chem Soc* **133**(17):6587-95 (2011). PMID: 21473576. PMC3090292.
433. Pier CL, Chen C, Tepp WH, Lin G, Janda KD, Barbieri JT, Pellett S, Johnson EA. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. *FEBS Lett* **585**(1):199-206 (2011). PMID: 21126520. PMC3041152.
434. Salzameda NT, Eubanks LM, Zakhari JS, Tsuchikama K, DeNunzio NJ, Allen KN, Hixon MS, Janda KD. A cross-over inhibitor of the botulinum neurotoxin light chain B: A natural product implicating an exosite mechanism of action. *Chem Commun (Camb)* **47**(6):1713-5 (2011). PMID: 21203627. PMC3065946.

435. Silhar P, Alakurtti S, Capkova K, Xiaochuan F, Shoemaker CB, Yli-Kauhaluoma J, Janda KD. Synthesis and evaluation of library of betulin derivatives against the botulinum neurotoxin A protease. *Bioorg Med Chem Lett* **21**(8):2229-31 (2011). PMID: 21421315. PMC3070790.
436. Stowe GN, Janda KD. A Diels-Alder reaction conducted within the parameters of aqueous organocatalysis: Still just smoke and mirrors. *Tetrahedron Lett* **52**(17):2085-7 (2011). PMID: 21516231. PMC3079225.
437. Stowe GN, Schlosburg JE, Vendruscolo LF, Edwards S, Misra KK, Schulteis G, Zakhari JS, Koob GF, Janda KD. Developing a vaccine against multiple psychoactive targets: A case study of heroin. *CNS Neurol Disord Drug Targets* **10**(8):865-75 (2011). PMID: 22229311. PMC3327724.
438. Stowe GN, Vendruscolo LF, Edwards S, Schlosburg JE, Misra KK, Schulteis G, Mayorov AV, Zakhari JS, Koob GF, Janda KD. A vaccine strategy that induces protective immunity against heroin. *J Med Chem* **54**(14):5195-204 (2011). PMID: 21692508. PMC3142939.
439. Treweek JB, Roberts AJ, Janda KD. Immunopharmacotherapeutic manifolds and modulation of cocaine overdose. *Pharmacol Biochem Behav* **98**(3):474-84 (2011). PMID: 21356233. PMC3069656.
440. Tsuchikama K, Lowery CA, Janda KD. Probing autoinducer-2 based quorum sensing: The biological consequences of molecules unable to traverse equilibrium states. *J Org Chem* **76**(17):6981-9 (2011). PMID: 21678949. PMC3162994.
441. Uckun FM, Qazi S, Ozer Z, Garner AL, Pitt J, Ma H, Janda KD. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. *Br J Haematol* **153**(6):741-52 (2011). PMID: 21517817.
442. Zakhari JS, Kinoyama I, Hixon MS, Di Mola A, Globisch D, Janda KD. Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-diaminopyridine prodrug design and characterization. *Bioorg Med Chem* **19**(21):6203-9 (2011). PMID: 21975066. PMC3196298.
443. Zakhari JS, Kinoyama I, Struss AK, Pullanikat P, Lowery CA, Lardy M, Janda KD. Synthesis and molecular modeling provide insight into a *Pseudomonas aeruginosa* quorum sensing conundrum. *J Am Chem Soc* **133**(11):3840-2 (2011). PMID: 21348514. PMC3060279.
444. Bremer PT, Janda KD. Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance. *J Med Chem* **55**(23):10776-80 (2012). PMID: 23134263. PMC3527012.
445. Garner AL, Struss AK, Fullagar JL, Agrawal A, Moreno AY, Cohen SM, Janda KD. 3-Hydroxy-1-alkyl-2-methylpyridine-4(1H)-thiones: Inhibition of the *Pseudomonas aeruginosa* virulence factor LasB. *ACS Med Chem Lett* **3**(8):668-72 (2012). PMID: 23181168. PMC3501683.
446. Globisch D, Lowery CA, McCague KC, Janda KD. Uncharacterized 4,5-dihydroxy-2,3-pentanedione (DPD) molecules revealed through NMR spectroscopy: Implications for a greater signaling diversity in bacterial species. *Angew Chem Int Ed Engl* **51**(17):4204-8 (2012). PMID: 22378693. PMC3505754.
447. Hicks MJ, Rosenberg JB, De BP, Pagovich OE, Young CN, Qiu JP, Kaminsky SM, Hackett NR, Worgall S, Janda KD, Davisson RL, Crystal RG. AAV-directed persistent expression of a

- gene encoding anti-nicotine antibody for smoking cessation. *Sci Transl Med* **4**(140):140ra87 (2012). PMID: 22745437. PMC3622954.
448. Kravchenko VV, Gloeckner C, Stowe GN, Kang YJ, Tobias PS, Mathison JC, Ulevitch RJ, Kaufmann GF, Janda KD. The use of small molecule probes to study spatially separated stimulus-induced signaling pathways. *Bioorg Med Chem Lett* **22**(5):2043-5 (2012). PMID: 22300658. PMC3288742.
449. Moreno AY, Azar MR, Koob GF, Janda KD. Probing the protective effects of a conformationally constrained nicotine vaccine. *Vaccine* **30**(47):6665-70 (2012). PMID: 22963803.
450. Romano AA, Hahn T, Davis N, Lowery CA, Struss AK, Janda KD, Bottger LH, Matzanke BF, Carrano CJ. The Fe(III) and Ga(III) coordination chemistry of 3-(1-hydroxymethylidene) and 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-dione: Novel tetramic acid degradation products of homoserine lactone bacterial quorum sensing molecules. *J Inorg Biochem* **107**(1):96-103 (2012). PMID: 22178671. PMC3258344.
451. Rosenberg JB, Hicks MJ, De BP, Pagovich O, Frenk E, Janda KD, Wee S, Koob GF, Hackett NR, Kaminsky SM, Worgall S, Tignor N, Mezey JG, Crystal RG. AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. *Hum Gene Ther* **23**(5):451-9 (2012). PMID: 22486244. PMC3360503.
452. Treweek JB, Janda KD. An antidote for acute cocaine toxicity. *Mol Pharm* **9**(4):969-78 (2012). PMID: 22380623. PMC3319285.
453. Tsuchikama K, Zhu J, Lowery CA, Kaufmann GF, Janda KD. C4-alkoxy-HPD: A potent class of synthetic modulators surpassing nature in AI-2 quorum sensing. *J Am Chem Soc* **134**(33):13562-4 (2012). PMID: 22866957. PMC3438919.
454. von Hoven G, Kloft N, Neukirch C, Ebinger S, Bobkiewicz W, Weis S, Boller K, Janda KD, Husmann M. Modulation of translation and induction of autophagy by bacterial exoproducts. *Med Microbiol Immunol* **201**(4):409-18 (2012). PMID: 22991039. PMC3470817.
455. Wee S, Hicks MJ, De BP, Rosenberg JB, Moreno AY, Kaminsky SM, Janda KD, Crystal RG, Koob GF. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. *Neuropsychopharmacology* **37**(5):1083-91 (2012). PMID: 21918504. PMC3306868.
456. Zakhari JS, Zorrilla EP, Zhou B, Mayorov AV, Janda KD. Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. *Mol Pharm* **9**(2):281-9 (2012). PMID: 22149064. PMC3273630.
457. Cai X, Tsuchikama K, Janda KD. Modulating cocaine vaccine potency through hapten fluorination. *J Am Chem Soc* **135**(8):2971-4 (2013). PMID: 23398531. PMC3637684.
458. Cai X, Whitfield T, Hixon MS, Grant Y, Koob GF, Janda KD. Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design. *J Med Chem* **56**(9):3701-9 (2013). PMID: 23627877. PMC3691275.
459. Cai X, Whitfield T, Moreno AY, Grant Y, Hixon MS, Koob GF, Janda KD. Probing the effects of hapten stability on cocaine vaccine immunogenicity. *Mol Pharm* **10**(11):4176-84 (2013). PMID: 23927436. PMC3946501.

460. De BP, Pagovich OE, Hicks MJ, Rosenberg JB, Moreno AY, Janda KD, Koob GF, Worgall S, Kaminsky SM, Sondhi D, Crystal RG. Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. *Hum Gene Ther* **24**(1):58-66 (2013). PMID: 23140508. PMC3555097.
461. Fullagar JL, Garner AL, Struss AK, Day JA, Martin DP, Yu J, Cai X, Janda KD, Cohen SM. Antagonism of a zinc metalloprotease using a unique metal-chelating scaffold: Tropolones as inhibitors of *P. aeruginosa* elastase. *Chem Commun (Camb)* **49**(31):3197-9 (2013). PMID: 23482955. PMC3618488.
462. Garner AL, Fullagar JL, Day JA, Cohen SM, Janda KD. Development of a high-throughput screen and its use in the discovery of *Streptococcus pneumoniae* immunoglobulin A1 protease inhibitors. *J Am Chem Soc* **135**(27):10014-7 (2013). PMID: 23808771. PMC3810181.
463. Garner AL, Yu J, Struss AK, Kaufmann GF, Kravchenko VV, Janda KD. Immunomodulation and the quorum sensing molecule 3-oxo-C12-homoserine lactone: The importance of chemical scaffolding for probe development. *Chem Commun (Camb)* **49**(15):1515-7 (2013). PMID: 23328974. PMC3566768.
464. Globisch D, Moreno AY, Hixon MS, Nunes AA, Denery JR, Specht S, Hoerauf A, Janda KD. *Onchocerca volvulus*-neurotransmitter tyramine is a biomarker for river blindness. *Proc Natl Acad Sci U S A* **110**(11):4218-23 (2013). PMID: 23440222. PMC3600455.
465. Kravchenko V, Garner AL, Mathison J, Seit-Nebi A, Yu J, Gileva IP, Ulevitch R, Janda KD. Facilitating cytokine-mediated cancer cell death by proteobacterial N-acylhomoserine lactones. *ACS Chem Biol* **8**(6):1117-20 (2013). PMID: 23517377. PMC3755046.
466. Lockner JW, Ho SO, McCague KC, Chiang SM, Do TQ, Fujii G, Janda KD. Enhancing nicotine vaccine immunogenicity with liposomes. *Bioorg Med Chem Lett* **23**(4):975-8 (2013). PMID: 23313243. PMC3557556.
467. Lowery CA, Adler M, Borrell A, Janda KD. Scorpion toxins for the reversal of BoNT-induced paralysis. *Bioorg Med Chem Lett* **23**(24):6743-6 (2013). PMID: 24252544. PMC3869784.
468. Lowery CA, Matamouros S, Niessen S, Zhu J, Scolnick J, Lively JM, Cravatt BF, Miller SI, Kaufmann GF, Janda KD. A chemical biology approach to interrogate quorum-sensing regulated behaviors at the molecular and cellular level. *Chem Biol* **20**(7):903-11 (2013). PMID: 23890008. PMC3736722.
469. Maoz A, Hicks MJ, Vallabhjousula S, Synan M, Kothari PJ, Dyke JP, Ballon DJ, Kaminsky SM, De BP, Rosenberg JB, Martinez D, Koob GF, Janda KD, Crystal RG. Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter. *Neuropsychopharmacology* **38**(11):2170-8 (2013). PMID: 23660705. PMC3773666.
470. Matyas GR, Mayorov AV, Rice KC, Jacobson AE, Cheng K, Iyer MR, Li F, Beck Z, Janda KD, Alving CR. Liposomes containing monophosphoryl lipid A: A potent adjuvant system for inducing antibodies to heroin hapten analogs. *Vaccine* **31**(26):2804-10 (2013). PMID: 23624097. PMC4120113.
471. Miller ML, Moreno AY, Aarde SM, Creehan KM, Vandewater SA, Vaillancourt BD, Wright MJ, Jr., Janda KD, Taffe MA. A methamphetamine vaccine attenuates methamphetamine-



- induced disruptions in thermoregulation and activity in rats. *Biol Psychiatry* **73**(8):721-8 (2013). PMID: 23098894. PMC3561477.
472. Rosenberg JB, De BP, Hicks MJ, Janda KD, Kaminsky SM, Worgall S, Crystal RG. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine. *Hum Gene Ther* **24**(6):595-603 (2013). PMID: 23611296. PMC3689186.
473. Schlosburg JE, Vendruscolo LF, Bremer PT, Lockner JW, Wade CL, Nunes AA, Stowe GN, Edwards S, Janda KD, Koob GF. Dynamic vaccine blocks relapse to compulsive intake of heroin. *Proc Natl Acad Sci U S A* **110**(22):9036-41 (2013). PMID: 23650354. PMC3670323.
474. Silhar P, Eubanks LM, Seki H, Pellett S, Javor S, Tepp WH, Johnson EA, Janda KD. Targeting botulinum A cellular toxicity: A prodrug approach. *J Med Chem* **56**(20):7870-9 (2013). PMID: 24127873. PMC3880648.
475. Silhar P, Lardy MA, Hixon MS, Shoemaker CB, Barbieri JT, Struss AK, Lively JM, Javor S, Janda KD. The C-terminus of botulinum A protease has profound and unanticipated kinetic consequences upon the catalytic cleft. *ACS Med Chem Lett* **4**(2):283-7 (2013). PMID: 23565325. PMC3615567.
476. Silhar P, Silvaggi NR, Pellett S, Capkova K, Johnson EA, Allen KN, Janda KD. Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: Synthesis, crystallography, modeling, kinetic and cellular based studies. *Bioorg Med Chem* **21**(5):1344-8 (2013). PMID: 23340139. PMC3574188.
477. Struss AK, Nunes A, Waalen J, Lowery CA, Pullanikat P, Denery JR, Conrad DJ, Kaufmann GF, Janda KD. Toward implementation of quorum sensing autoinducers as biomarkers for infectious disease states. *Anal Chem* **85**(6):3355-62 (2013). PMID: 23391272. PMC3604138.
478. Zhu J, Hixon MS, Globisch D, Kaufmann GF, Janda KD. Mechanistic insights into the LsrK kinase required for autoinducer-2 quorum sensing activation. *J Am Chem Soc* **135**(21):7827-30 (2013). PMID: 23672516. PMC3736694.
479. Bremer PT, Hixon MS, Janda KD. Benzoquinones as inhibitors of botulinum neurotoxin serotype A. *Bioorg Med Chem* **22**(15):3971-81 (2014). PMID: 24984937. PMC4138410.
480. Bremer PT, Schlosburg JE, Lively JM, Janda KD. Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy. *Mol Pharm* **11**(3):1075-80 (2014). PMID: 24517171. PMC3993894.
481. Collins KC, Janda KD. Investigating hapten clustering as a strategy to enhance vaccines against drugs of abuse. *Bioconjug Chem* **25**(3):593-600 (2014). PMID: 24521489. PMC3983143.
482. Collins KC, Schlosburg JE, Lockner JW, Bremer PT, Ellis BA, Janda KD. Lipid tucaresol as an adjuvant for methamphetamine vaccine development. *Chem Commun (Camb)* **50**(31):4079-81 (2014). PMID: 24615284. PMC4033696.
483. Eubanks LM, Ellis BA, Cai X, Schlosburg JE, Janda KD. A human recombinant monoclonal antibody to cocaine: Preparation, characterization and behavioral studies. *Bioorg Med Chem Lett* **24**(19):4664-6 (2014). PMID: 25205191. PMC4185020.
484. Gooyit M, Tricoche N, Lustigman S, Janda KD. Dual protonophore-chitinase inhibitors dramatically affect *O. volvulus* molting. *J Med Chem* **57**(13):5792-9 (2014). PMID: 24918716. PMC4216208.

485. Harris TL, Lowery CA, Hixon MS, Janda KD. A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity. *ACS Chem Neurosci* **5**(8):632-6 (2014). PMID: 25000171. PMC4140587.
486. Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, Rhee JK, Baksh MM, Stefan E, Hartl M, Bister K, Vogt PK, Janda KD. Inhibitor of MYC identified in a Kröhnke pyridine library. *Proc Natl Acad Sci U S A* **111**(34):12556-61 (2014). PMID: 25114221. PMC4151726.
487. Hicks MJ, Kaminsky SM, De BP, Rosenberg JB, Evans SM, Foltin RW, Andrenyak DM, Moody DE, Koob GF, Janda KD, Ricart Arbona RJ, Lepherd ML, Crystal RG. Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine. *Hum Gene Ther Clin Dev* **25**(1):40-9 (2014). PMID: 24649839. PMC4047994.
488. Jacob NT, Lockner JW, Kravchenko VV, Janda KD. Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL. *Angew Chem Int Ed Engl* **53**(26):6628-31 (2014). PMID: 24838721.
489. Raffener P, Röck R, Schraffl A, Hartl M, Hart JR, Janda KD, Vogt PK, Stefan E, Bister K. In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. *Oncotarget* **5**(19):8869-78 (2014). PMID: 25326649. PMC4253403.
490. Seki H, Pellett S, Silhar P, Stowe GN, Blanco B, Lardy MA, Johnson EA, Janda KD. Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain. *Bioorg Med Chem* **22**(3):1208-17 (2014). PMID: 24360826. PMC3919520.
491. Xue S, Javor S, Hixon MS, Janda KD. Probing BoNT/A protease exosites: Implications for inhibitor design and light chain longevity. *Biochemistry* **53**(43):6820-4 (2014). PMID: 25295706. PMC4222541.
492. Cai X, Janda KD. A chemoenzymatic approach toward the preparation of site-specific antibody–drug conjugates. *Tetrahedron Lett* **56**(23):3172-5 (2015).
493. Collins KC, Janda KD. Hapten design for anti-addiction vaccine development. In: *Biologics to Treat Substance Abuse Disorders: Vaccines, Monoclonal Antibodies, and Enzymes*. Montoya ID (ed.). Springer. 2015, p. 327-65.
494. Globisch D, Specht S, Pfarr KM, Eubanks LM, Hoerauf A, Janda KD. *Litomosoides sigmodontis*: A jird urine metabolome study. *Bioorg Med Chem Lett* **25**(24):5804-7 (2015). PMID: 26573416.
495. Gooyit M, Harris TL, Tricoche N, Javor S, Lustigman S, Janda KD. *Onchocerca volvulus* molting inhibitors identified through scaffold hopping. *ACS Infect Dis* **1**(5):198-202 (2015). PMID: 27622649.
496. Gooyit M, Tricoche N, Javor S, Lustigman S, Janda KD. Exploiting the polypharmacology of  $\beta$ -carboline to disrupt *O. volvulus* molting. *ACS Med Chem Lett* **6**(3):339-43 (2015). PMID: 25815157. PMC4360149.
497. Lockner JW, Eubanks LM, Choi JL, Lively JM, Schlosburg JE, Collins KC, Globisch D, Rosenfeld-Gunn RJ, Wilson IA, Janda KD. Flagellin as carrier and adjuvant in cocaine vaccine development. *Mol Pharm* **12**(2):653-62 (2015). PMID: 25531528. PMC4319694.
498. Lockner JW, Lively JM, Collins KC, Vendruscolo JC, Azar MR, Janda KD. A conjugate vaccine using enantiopure hapten imparts superior nicotine-binding capacity. *J Med Chem* **58**(2):1005-11 (2015). PMID: 25493909.

499. Miller ML, Aarde SM, Moreno AY, Creehan KM, Janda KD, Taffe MA. Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats. *Drug Alcohol Depend* **153**:29-36 (2015). PMID: 26118833. PMC4509945.
500. Pippione AC, Dosio F, Ducime A, Federico A, Martina K, Sainas S, Frølund B, Gooyit M, Janda KD, Boschi D, Lolli ML. Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches. *MedChemComm* **6**(7):1285-92 (2015).
501. Seki H, Xue S, Hixon MS, Pellett S, Remes M, Johnson EA, Janda KD. Toward the discovery of dual inhibitors for botulinum neurotoxin A: Concomitant targeting of endocytosis and light chain protease activity. *Chem Commun (Camb)* **51**(28):6226-9 (2015). PMID: 25759983.
502. Xue S, Schlosburg JE, Janda KD. A new strategy for smoking cessation: Characterization of a bacterial enzyme for the degradation of nicotine. *J Am Chem Soc* **137**(32):10136-9 (2015). PMID: 26237398.
503. Zhu J, Cai X, Harris TL, Gooyit M, Wood M, Lardy M, Janda KD. Disarming *Pseudomonas aeruginosa* virulence factor LasB by leveraging a *Caenorhabditis elegans* infection model. *Chem Biol* **22**(4):483-91 (2015). PMID: 25892201.
504. Bremer PT, Kimishima A, Schlosburg JE, Zhou B, Collins KC, Janda KD. Combatting synthetic designer opioids: A conjugate vaccine ablates lethal doses of fentanyl class drugs. *Angew Chem Int Ed Engl* **55**(11):3772-5 (2016). PMID: 26879590. PMC4860013.
505. Bremer PT, Xue S, Janda KD. Picolinic acids as  $\beta$ -exosite inhibitors of botulinum neurotoxin A light chain. *Chem Commun (Camb)* **52**(84):12521-4 (2016). PMID: 27722252. PMC5085802.
506. Collins KC, Schlosburg JE, Bremer PT, Janda KD. Methamphetamine vaccines: Improvement through hapten design. *J Med Chem* **59**(8):3878-85 (2016). PMID: 27054372. PMC5895457.
507. Collins KC, Tsuchikama K, Lowery CA, Zhu J, Janda KD. Dissecting AI-2-mediated quorum sensing through C5-analogue synthesis and biochemical analysis. *Tetrahedron* **72**(25):3593-8 (2016). PMID: 27340303. PMC4915392.
508. Evans SM, Foltin RW, Hicks MJ, Rosenberg JB, De BP, Janda KD, Kaminsky SM, Crystal RG. Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacquisition using a choice procedure in rhesus macaques. *Pharmacol Biochem Behav* **150-151**:76-86 (2016). PMID: 27697554. PMC5145743.
509. Gooyit M, Janda KD. Reprofiled anthelmintics abate hypervirulent stationary-phase *Clostridium difficile*. *Sci Rep* **6**:33642 (2016). PMID: 27633064. PMC5025651.
510. Gooyit MD, Janda KD. Modulation of the surface-layer protein of *Clostridium difficile* through Cwp84 inhibition. *ACS Infect Dis* **2**(7):465-70 (2016). PMID: 27626098.
511. Harris TL, Wenthur CJ, Diego-Taboada A, Mackenzie G, Corbitt TS, Janda KD. *Lycopodium clavatum* exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication. *Chem Commun (Camb)* **52**(22):4187-90 (2016). PMID: 26906286. PMC7544009.
512. Hart JR, Weinberg MS, Morris KV, Roberts TC, Janda KD, Garner AL, Vogt PK. MINCR is not a MYC-induced lncRNA. *Proc Natl Acad Sci U S A* **113**(5):E496-7 (2016). PMID: 26811502. PMC4747730.

513. Jacob NT, Lockner JW, Schlosburg JE, Ellis BA, Eubanks LM, Janda KD. Investigations of enantiopure nicotine haptens using an adjuvanting carrier in anti-nicotine vaccine development. *J Med Chem* **59**(6):2523-9 (2016). PMID: 26918428.
514. Kimishima A, Wenthur CJ, Eubanks LM, Sato S, Janda KD. Cocaine vaccine development: Evaluation of carrier and adjuvant combinations that activate multiple Toll-like receptors. *Mol Pharm* **13**(11):3884-90 (2016). PMID: 27717287. PMC6381837.
515. Seki H, Xue S, Pellett S, Silhar P, Johnson EA, Janda KD. Cellular protection of SNAP-25 against botulinum neurotoxin/A: Inhibition of thioredoxin reductase through a suicide substrate mechanism. *J Am Chem Soc* **138**(17):5568-75 (2016). PMID: 27070533. PMC4881748.
516. Tararina MA, Janda KD, Allen KN. Structural analysis provides mechanistic insight into nicotine oxidoreductase from *Pseudomonas putida*. *Biochemistry* **55**(48):6595-8 (2016). PMID: 27933790. PMC6250430.
517. Tsuchikama K, Gooyit M, Harris TL, Zhu J, Globisch D, Kaufmann GF, Janda KD. Glycation reactivity of a quorum-sensing signaling molecule. *Angew Chem Int Ed Engl* **55**(12):4002-6 (2016). PMID: 26890076. PMC4965832.
518. Zhou B, Eubanks LM, Jacob NT, Ellis B, Roberts AJ, Janda KD. Studies towards the improvement of an anti-cocaine monoclonal antibody for treatment of acute overdose. *Bioorg Med Chem Lett* **26**(20):5078-81 (2016). PMID: 27599743. PMC5050165.
519. Anraku K, Sato S, Jacob NT, Eubanks LM, Ellis BA, Janda KD. The design and synthesis of an alpha-Gal trisaccharide epitope that provides a highly specific anti-Gal immune response. *Org Biomol Chem* **15**(14):2979-92 (2017). PMID: 28294277. PMC5476458.
520. Bremer PT, Adler M, Phung CH, Singh AK, Janda KD. Newly designed quinolinol inhibitors mitigate the effects of botulinum neurotoxin A in enzymatic, cell-based, and ex vivo assays. *J Med Chem* **60**(1):338-48 (2017). PMID: 27966961. PMC5496736.
521. Bremer PT, Janda KD. Conjugate vaccine immunotherapy for substance use disorder. *Pharmacol Rev* **69**(3):298-315 (2017). PMID: 28634286. PMC5482184.
522. Bremer PT, Pellett S, Carolan JP, Tepp WH, Eubanks LM, Allen KN, Johnson EA, Janda KD. Metal ions effectively ablate the action of botulinum neurotoxin A. *J Am Chem Soc* **139**(21):7264-72 (2017). PMID: 28475321. PMC5612488.
523. Bremer PT, Schlosburg JE, Banks ML, Steele FF, Zhou B, Poklis JL, Janda KD. Development of a clinically viable heroin vaccine. *J Am Chem Soc* **139**(25):8601-11 (2017). PMID: 28574716. PMC5612493.
524. Globisch D, Eubanks LM, Shirey RJ, Pfarr KM, Wanji S, Debrah AY, Hoerauf A, Janda KD. Validation of onchocerciasis biomarker N-acetyltyramine-O-glucuronide (NATOG). *Bioorg Med Chem Lett* **27**(15):3436-40 (2017). PMID: 28600214. PMC5510726.
525. Gooyit M, Miranda PO, Wenthur CJ, Ducime A, Janda KD. Influencing antibody-mediated attenuation of methamphetamine CNS distribution through vaccine linker design. *ACS Chem Neurosci* **8**(3):468-72 (2017). PMID: 27958709. PMC5711417.
526. Hwang CS, Janda KD. A vision for vaccines: Combating the opioid epidemic. *Biochemistry* **56**(42):5625-7 (2017). PMID: 28994583.
527. Jacob NT, Anraku K, Kimishima A, Zhou B, Collins KC, Lockner JW, Ellis BA, Janda KD. A bioconjugate leveraging xenoreactive antibodies to alleviate cocaine-induced behavior. *Chem Commun (Camb)* **53**(58):8156-9 (2017). PMID: 28677711. PMC5559285.

528. Kimishima A, Wenthur CJ, Zhou B, Janda KD. An advance in prescription opioid vaccines: Overdose mortality reduction and extraordinary alteration of drug half-life. *ACS Chem Biol* **12**(1):36-40 (2017). PMID: 28103678. PMC6434689.
529. Nguyen JD, Bremer PT, Ducime A, Creehan KM, Kisby BR, Taffe MA, Janda KD. Active vaccination attenuates the psychostimulant effects of  $\alpha$ -PVP and MDPV in rats. *Neuropharmacology* **116**:1-8 (2017). PMID: 27956054. PMC5385148.
530. Nguyen JD, Bremer PT, Hwang CS, Vandewater SA, Collins KC, Creehan KM, Janda KD, Taffe MA. Effective active vaccination against methamphetamine in female rats. *Drug Alcohol Depend* **175**:179-86 (2017). PMID: 28437722. PMC5484075.
531. Srinivasulu V, Janda KD, Abu-Yousef IA, O'Connor MJ, Al-Tel TH. A modular CuI-L-proline catalyzed one-pot route for the rapid access of constrained and privileged hetero-atom-linked medium-sized ring systems. *Tetrahedron* **73**(15):2139-50 (2017).
532. Wenthur CJ, Cai X, Ellis BA, Janda KD. Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination. *Bioorg Med Chem Lett* **27**(16):3666-8 (2017). PMID: 28709828. PMC5584565.
533. Wenthur CJ, Zhou B, Janda KD. Vaccine-driven pharmacodynamic dissection and mitigation of fenethylamine psychoactivity. *Nature* **548**(7668):476-9 (2017). PMID: 28813419. PMC5957549.
534. Xue S, Seki H, Remes M, Silhar P, Janda K. Examination of alpha-exosite inhibitors against Botulinum neurotoxin A protease through structure-activity relationship studies of chicoric acid. *Bioorg Med Chem Lett* **27**(22):4956-9 (2017). PMID: 29050781. PMC5667901.
535. Banks ML, Olson ME, Janda KD. Immunopharmacotherapies for treating opioid use disorder. *Trends Pharmacol Sci* **39**(11):908-11 (2018). PMID: 30343725. PMC6472257.
536. Disney MD, Janda KD. Introduction. *Bioorg Med Chem Lett* **28**(16):2661-2 (2018). PMID: 30029841.
537. Galinato MH, Lockner JW, Fannon-Pavlich MJ, Sobieraj JC, Staples MC, Somkuwar SS, Ghofranian A, Chaing S, Navarro AI, Joea A, Luikart BW, Janda KD, Heyser C, Koob GF, Mandyam CD. A synthetic small-molecule Isoxazole-9 protects against methamphetamine relapse. *Mol Psychiatry* **23**(3):629-38 (2018). PMID: 28348387. PMC5617764.
538. Hwang CS, Bremer PT, Wenthur CJ, Ho SO, Chiang S, Ellis B, Zhou B, Fujii G, Janda KD. Enhancing efficacy and stability of an antiheroin vaccine: Examination of antinociception, opioid binding profile, and lethality. *Mol Pharm* **15**(3):1062-72 (2018). PMID: 29420901. PMC5912936.
539. Hwang CS, Smith LC, Natori Y, Ellis B, Zhou B, Janda KD. Improved admixture vaccine of fentanyl and heroin hapten immunoconjugates: Antinociceptive evaluation of fentanyl-contaminated heroin. *ACS Omega* **3**(9):11537-43 (2018). PMID: 30288464. PMC6166218.
540. Hwang CS, Smith LC, Natori Y, Ellis B, Zhou B, Janda KD. Efficacious vaccine against heroin contaminated with fentanyl. *ACS Chem Neurosci* **9**(6):1269-75 (2018). PMID: 29558798. PMC6013375.
541. Jacob NT, Miranda PO, Shirey RJ, Gautam R, Zhou B, de Orbe Izquierdo ME, Hixon MS, Hart JR, Ueno L, Vogt PK, Janda KD. Synthetic molecules for disruption of the MYC

- protein-protein interface. *Bioorg Med Chem* **26**(14):4234-9 (2018). PMID: 30037753. PMC6214403.
542. Kallupi M, Xue S, Zhou B, Janda KD, George O. An enzymatic approach reverses nicotine dependence, decreases compulsive-like intake, and prevents relapse. *Sci Adv* **4**(10):eaat4751 (2018). PMID: 30345354. PMC6192681.
543. Kimishima A, Olson ME, Janda KD. Investigations into the efficacy of multi-component cocaine vaccines. *Bioorg Med Chem Lett* **28**(16):2779-83 (2018). PMID: 29317163. PMC6013332.
544. Kimishima A, Olson ME, Natori Y, Janda KD. Efficient syntheses of cocaine vaccines and their in vivo evaluation. *ACS Med Chem Lett* **9**(5):411-6 (2018). PMID: 29795751. PMC5949726.
545. Miranda PO, Cubitt B, Jacob NT, Janda KD, de la Torre JC. Mining a Kröhnke pyridine library for anti-arenavirus activity. *ACS Infect Dis* **4**(5):815-24 (2018). PMID: 29405696.
546. Nguyen JD, Hwang CS, Grant Y, Janda KD, Taffe MA. Prophylactic vaccination protects against the development of oxycodone self-administration. *Neuropharmacology* **138**:292-303 (2018). PMID: 29936242. PMC6800241.
547. Olson ME, Janda KD. Vaccines to combat the opioid crisis: Vaccines that prevent opioids and other substances of abuse from entering the brain could effectively treat addiction and abuse. *EMBO Rep* **19**(1):5-9 (2018). PMID: 29237715. PMC5757212.
548. Shirey RJ, Globisch D, Eubanks LM, Hixon MS, Janda KD. Noninvasive urine biomarker lateral flow immunoassay for monitoring active onchocerciasis. *ACS Infect Dis* **4**(10):1423-31 (2018). PMID: 30141624. PMC6189908.
549. Tararina MA, Xue S, Smith LC, Muellers SN, Miranda PO, Janda KD, Allen KN. Crystallography coupled with kinetic analysis provides mechanistic underpinnings of a nicotine-degrading enzyme. *Biochemistry* **57**(26):3741-51 (2018). PMID: 29812904. PMC6295333.
550. Xue S, Kallupi M, Zhou B, Smith LC, Miranda PO, George O, Janda KD. An enzymatic advance in nicotine cessation therapy. *Chem Commun (Camb)* **54**(14):1686-9 (2018). PMID: 29308799. PMC6231713.
551. Hwang CS, Ellis B, Zhou B, Janda KD. Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin. *Bioorg Med Chem* **27**(1):125-32 (2019). PMID: 30497790. PMC6442938.
552. Hwang CS, Smith LC, Wenthur CJ, Ellis B, Zhou B, Janda KD. Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences. *Vaccine* **37**(30):4155-63 (2019). PMID: 31176539. PMC6658211.
553. Lin L, Olson ME, Eubanks LM, Janda KD. Strategies to counteract botulinum neurotoxin A: Nature's deadliest biomolecule. *Acc Chem Res* **52**(8):2322-31 (2019). PMID: 31322847. PMC7478247.
554. Natori Y, Hwang CS, Lin L, Smith LC, Zhou B, Janda KD. A chemically contiguous hapten approach for a heroin-fentanyl vaccine. *Beilstein J Org Chem* **15**:1020-31 (2019). PMID: 31164940. PMC6541359.
555. Nguyen JD, Grant Y, Creehan KM, Hwang CS, Vandewater SA, Janda KD, Cole M, Taffe MA.  $\Delta^9$ -tetrahydrocannabinol attenuates oxycodone self-administration under extended

- access conditions. *Neuropharmacology* **151**:127-35 (2019). PMID: 30980837. PMC6510273.
556. Olson ME, Eubanks LM, Janda KD. Chemical interventions for the opioid crisis: Key advances and remaining challenges. *J Am Chem Soc* **141**(5):1798-806 (2019). PMID: 30532973.
557. Olson ME, Sugane T, Zhou B, Janda KD. Consequence of hapten stereochemistry: An efficacious methamphetamine vaccine. *J Am Chem Soc* **141**(36):14089-92 (2019). PMID: 31479256.
558. Smith LC, Bremer PT, Hwang CS, Zhou B, Ellis B, Hixon MS, Janda KD. Monoclonal antibodies for combating synthetic opioid intoxication. *J Am Chem Soc* **141**(26):10489-503 (2019). PMID: 31187995. PMC6662938.
559. Smith LC, Lin L, Hwang CS, Zhou B, Kubitz DM, Wang H, Janda KD. Lateral flow assessment and unanticipated toxicity of Kratom. *Chem Res Toxicol* **32**(1):113-21 (2019). PMID: 30380840. PMC6662923.
560. Tenney RD, Blake S, Bremer PT, Zhou B, Hwang CS, Poklis JL, Janda KD, Banks ML. Vaccine blunts fentanyl potency in male rhesus monkeys. *Neuropharmacology* **158**:107730 (2019). PMID: 31369740. PMC6745253.
561. Townsend EA, Blake S, Faunce KE, Hwang CS, Natori Y, Zhou B, Bremer PT, Janda KD, Banks ML. Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats. *Neuropsychopharmacology* **44**(10):1681-9 (2019). PMID: 31043682. PMC6784909.
562. Wang J, Merino DM, Light N, Murphy BL, Wang YD, Guo X, Hodges AP, Chau LQ, Liu KW, Dhall G, Asgharzadeh S, Kiehna EN, Shirey RJ, Janda KD, Taylor MD, Malkin D, Ellison DW, VandenBerg SR, Eberhart CG, Sears RC, Roussel MF, Gilbertson RJ, Wechsler-Reya RJ. Myc and loss of p53 cooperate to drive formation of choroid plexus carcinoma. *Cancer Res* **79**(9):2208-19 (2019). PMID: 30885981. PMC6497574.
563. Wenthur CJ, Gautam R, Zhou B, Vendruscolo LF, Leggio L, Janda KD. Ghrelin receptor influence on cocaine reward is not directly dependent on peripheral acyl-ghrelin. *Sci Rep* **9**(1):1841 (2019). PMID: 30755699. PMC6372697.
564. Belz TF, Bremer PT, Zhou B, Blake S, Ellis B, Eubanks LM, Janda KD. Sulfonate-isosteric replacement examined within heroin-hapten vaccine design. *Bioorg Med Chem Lett* **30**(17):127388 (2020). PMID: 32738981. PMC7398700.
565. Belz TF, Bremer PT, Zhou B, Ellis B, Eubanks LM, Janda KD. Enhancement of a heroin vaccine through hapten deuteration. *J Am Chem Soc* **142**(31):13294-8 (2020). PMID: 32700530. PMC7544008.
566. Belz TF, Olson ME, Giang E, Law M, Janda KD. Evaluation of a series of lipidated tucarecol adjuvants in a hepatitis C virus vaccine model. *ACS Med Chem Lett* **11**(12):2428-32 (2020). PMID: 33335664. PMC7734796.
567. Blake S, Thanissery R, Rivera AJ, Hixon MS, Lin M, Theriot CM, Janda KD. Salicylanilide analog minimizes relapse of *Clostridioides difficile* infection in mice. *J Med Chem* **63**(13):6898-908 (2020). PMID: 32482070.
568. Janda KD, Iadarola MJ. Standing out from the crowd in treating COVID-19. *Med Drug Discov* **6**:100034 (2020). PMID: 32292907. PMC7147214.

569. Kyzer JL, McGuire M, Park H, Belz TF, Bonakdar R, Janda KD, Wenthur CJ. Anti-opioid antibodies in individuals using chronic opioid therapy for lower back pain. *ACS Pharmacol Transl Sci* **3**(5):896-906 (2020). PMID: 33073189. PMC7551707
570. Lee JC, Kim HY, Lee S, Shin J, Kim HV, Kim K, Baek S, Lee D, Jeon H, Kim D, Yang SH, Han G, Park K, Choi J, Park J, Moss JA, Janda KD, Kim Y. Discovery of chemicals to either clear or indicate amyloid aggregates by targeting memory-impairing anti-parallel abeta dimers. *Angew Chem Int Ed Engl* **59**(28):11491-500 (2020). PMID: 32233096.
571. Lin L, Olson ME, Sugane T, Turner LD, Tararina MA, Nielsen AL, Kurbanov EK, Pellett S, Johnson EA, Cohen SM, Allen KN, Janda KD. Catch and anchor approach to combat both toxicity and longevity of botulinum toxin A. *J Med Chem* **63**(19):11100-20 (2020). PMID: 32886509. PMC7581224.
572. Natori Y, Kim D J. Synthesis of drug vaccine against heroin contaminated with fentanyl and their biological evaluation. *J Synth Org Chem Jpn* **78**(9):875-85 (2020).
573. Townsend EA, Bremer PT, Faunce KE, Negus SS, Jaster AM, Robinson HL, Janda KD, Banks ML. Evaluation of a dual fentanyl/heroin vaccine on the antinociceptive and reinforcing effects of a fentanyl/heroin mixture in male and female rats. *ACS Chem Neurosci* **11**(9):1300-10 (2020). PMID: 32271538. PMC7531604.
574. Wang J, Ellis B, Zhou B, Eubanks LM, Blake S, Janda KD. A fentanyl vaccine constructed upon opsonizing antibodies specific for the Galalpha1-3Gal epitope. *Chem Commun (Camb)* **56**(48):6551-4 (2020). PMID: 32396160. PMC7398699.
575. Belz TF, Lin M, Eubanks LM, Ellis B, Janda KD. Vaccine design through transition state mimicry of heroin hydrolysis. *Tetrahedron Lett* **71**:153045 (2021).
576. Blake S, Bremer PT, Zhou B, Petrovsky N, Smith LC, Hwang CS, Janda KD. Developing translational vaccines against heroin and fentanyl through investigation of adjuvants and stability. *Mol Pharm* **18**(1):228-35 (2021). PMID: 33301675.
577. Blake S, Shaabani N, Eubanks LM, Maruyama J, Manning JT, Beutler N, Paessler S, Ji H, Teijaro JR, Janda KD. Salicylanilides reduce SARS-CoV-2 replication and suppress induction of inflammatory cytokines in a rodent model. *ACS Infect Dis* **7**(8):2229-37 (2021). PMID: 34339171. PMC8353890.
578. Eubanks LM, Blake S, Natori Y, Ellis B, Bremer PT, Janda KD. A highly efficacious carfentanil vaccine that blunts opioid-induced antinociception and respiratory depression. *ACS Chem Biol* **16**(2):277-82 (2021). PMID: 33533592. PMC8260150.
579. Lee JC, Janda KD. Immunopharmacotherapeutic advancements in addressing methamphetamine abuse. *RSC Chem Biol* **2**(1):77-93 (2021). PMID: 34458776. PMC8341824.
580. Lin L, Turner LD, Silhar P, Pellett S, Johnson EA, Janda KD. Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A. *RSC Med Chem* **12**(1):137-43 (2021). PMID: 34046606. PMC8130615.
581. Lin M, Ellis B, Eubanks LM, Janda KD. Pharmacokinetic approach to combat the synthetic cannabinoid PB-22. *ACS Chem Neurosci* **12**(14):2573-9 (2021). PMID: 34254505.
582. Lin M, Lee JC, Blake S, Ellis B, Eubanks LM, Janda KD. Broadly neutralizing synthetic cannabinoid vaccines. *JACS Au* **1**(1):31-40 (2021). PMID: 34467269. PMC8395583.



584. Park H, Lee JC, Eubanks LM, Ellis B, Zhou B, Janda KD. Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin. *Bioorg Med Chem* **41**:116225 (2021). PMID: 34034147.
585. Rayo J, Gregor R, Jacob NT, Dandela R, Dubinsky L, Yashkin A, Aranovich A, Thangaraj M, Ernst O, Barash E, Malitsky S, Florea BI, Krom BP, Wiemer EAC, Kickhoefer VA, Rome LH, Mathison JC, Kaufmann GF, Overkleeft HS, Cravatt BF, Zor T, Janda KD, Ulevitch RJ, Kravchenko VV, Meijler MM. Immunoediting role for major vault protein in apoptotic signaling induced by bacterial N-acyl homoserine lactones. *Proc Natl Acad Sci U S A* **118**(12) (2021). PMID: 33723037. PMC8000436.
586. Shirey RJ, Hart JR, Sridharan B, Novick SJ, Turner LD, Zhou B, Nielsen AL, Eubanks LM, Ueno L, Hixon MS, Lairson LL, Spicer TP, Scampavia LD, Griffin PR, Vogt PK, Janda KD. Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay. *Bioorg Med Chem* **42**:116246 (2021). PMID: 34130216. PMC8279689.
587. Shirey RJ, Turner LD, Lairson LL, Janda KD. Modulators of immunoregulatory exonucleases PLD3 and PLD4 identified by high-throughput screen. *Bioorg Med Chem Lett* **49**:128293 (2021). PMID: 34332037.
588. Staples MC, Herman MA, Lockner JW, Avchalumov Y, Kharidia KM, Janda KD, Roberto M, Mandyam CD. Isoxazole-9 reduces enhanced fear responses and retrieval in ethanol-dependent male rats. *J Neurosci Res* **99**(11):3047-65 (2021). PMID: 34496069.
589. Tararina MA, Dam KK, Dhingra M, Janda KD, Palfey BA, Allen KN. Fast kinetics reveals rate-limiting oxidation and the role of the aromatic cage in the mechanism of the nicotine-degrading enzyme NicA2. *Biochemistry* **60**(4):259-73 (2021). PMID: 33464876.
590. Townsend EA, Bremer PT, Jacob NT, Negus SS, Janda KD, Banks ML. A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys. *Drug Alcohol Depend* **218**:108348 (2021). PMID: 33268227. PMC8224470.
591. Turner LD, Nielsen AL, Lin L, Campedelli AJ, Silvaggi NR, Chen JS, Wakefield AE, Allen KN, Janda KD. Use of crystallography and molecular modeling for the inhibition of the botulinum neurotoxin A protease. *ACS Med Chem Lett* **12**(8):1318-24 (2021). PMID: 34413962. PMC8365998.
592. Turner LD, Nielsen AL, Lin L, Pellett S, Sugane T, Olson ME, Johnson EA, Janda KD. Irreversible inhibition of BoNT/A protease: Proximity-driven reactivity contingent upon a bifunctional approach. *RSC Med Chem* **12**(6):960-9 (2021). PMID: 34223161. PMC8221255.
593. Lee JC, Eubanks LM, Zhou B, Janda KD. Development of an effective monoclonal antibody against heroin and its metabolites reveals therapies have mistargeted 6-monoacetylmorphine and morphine over heroin. *ACS Cent Sci* **8**(10):1464-70 (2022). PMID: 36313156. PMC9615117.
594. Lee JC, Janda KD. Development of effective therapeutics for polysubstance use disorders. *Curr Opin Chem Biol* **66**:102105 (2022). PMID: 34936944.
595. Lee JC, Park H, Eubanks LM, Ellis B, Zhou B, Janda KD. A vaccine against benzimidazole-derived new psychoactive substances that are more potent than fentanyl. *J Med Chem* **65**(3):2522-31 (2022). PMID: 34994550.

596. Lin M, Marin A, Ellis B, Eubanks LM, Andrianov AK, Janda KD. Polyphosphazene: A new adjuvant platform for cocaine vaccine development. *Mol Pharm* **19**(9):3358-66 (2022). PMID: 35984034.
597. Patel EN, Lin L, Sneller MM, Eubanks LM, Tepp WH, Pellett S, Janda KD. Investigation of salicylanilides as botulinum toxin antagonists. *ACS Infect Dis* **8**(8):1637-45 (2022). PMID: 35877209. PMC9592073.
598. Patel EN, Turner LD, Hixon MS, Janda KD. Identification of slow-binding inhibitors of the BoNT/A protease. *ACS Med Chem Lett* **13**(4):742-7 (2022). PMID: 35450355. PMC9014515.
599. Karadkhelkar NM, Lin M, Eubanks LM, Janda KD. Demystifying the Druggability of the MYC Family of Oncogenes. *J Am Chem Soc* **145**(6):3259-69 (2023). PMID: 36734615.
600. Lin L, Patel EN, Nielsen AL, Turner LD, Tepp WH, Nguyen K, Pellett S, Janda K. Transformation of a metal chelate into a “catch and anchor” inhibitor of Botulinum A protease. *Int J Mol Sci* **24**(5):4303 (2023). PMID: 36901734. PMC10001950.
601. Lin M, Eubanks LM, Karadkhelkar NM, Blake S, Janda KD. Catalytic Antibody Blunts Carfentanil-Induced Respiratory Depression. *ACS Pharmacol Transl Sci.* **6**(5):802-811 (2023). PMID: 37200811; PMCID: PMC10186356.